2015 annual report

how someday becomes today

MICAYLA WYNN
CHRONIC MYELOID LEUKEMIA SURVIVOR
Every day brings more proof of The Leukemia & Lymphoma Society’s impact on the cancer treatment landscape, and our leadership was especially apparent in Fiscal Year 2015. New therapies for blood cancers are being discovered faster than ever before and those same treatments are also being tested for patients with other cancers like breast, colon and pancreatic cancer, and serious diseases like rheumatoid arthritis. And we continue to work diligently every day to ensure that all blood cancer patients have access to the treatments they so desperately need.
Thanks to you, The Leukemia & Lymphoma Society (LLS) is a driving force in making someday today for the more than 1.2 million people in the United States living with a blood cancer. From the strong science and advances in research you are helping us to spearhead, to wins in advocating for patients with legislators and policymakers, to helping newly diagnosed patients navigate their treatment, we continue to earn our leadership mantle as the voice for all blood cancer patients. Patients, caregivers and donors continually inspire us to keep investing in lifesaving breakthroughs.

We raised awareness about blood cancers and the LLS mission through a wide array of media and communications channels in Fiscal Year 2015. You’ll see this, for example, in our support of the PBS documentary, “Ken Burns Presents Cancer: The Emperor of All Maladies,” which allowed LLS to showcase our historic role in advancing blood cancer treatments.

Our Therapy Acceleration Program continues to bridge the gap between discoveries in the laboratory and drug development, and this past year we entered into partnerships with even more biotechnology companies working on cutting-edge drug discovery and development programs. We continue to lead the charge against acute myeloid leukemia (AML) – now the most frequently diagnosed leukemia in adults – through the Harry T. Mangurian, Jr. Foundation Beat AML collaboration, changing the paradigm of how patients with AML are treated.

Fiscal Year 2015 also saw advances in therapies for patients with chronic lymphocytic leukemia (CLL), and a first-ever therapy indicated specifically for patients diagnosed with the rare Waldenstrom’s macroglobulinemia.

We continued to help patients when they were diagnosed by providing critical support and information through our Information Resource Center, which received more than 60,000 calls from patients, families, and caregivers this past year alone. And, our advocacy efforts paid off this year with five additional states adopting oral parity legislation and the near unanimous passage in the U.S. House of Representatives of the 21st Century Cures Act, designed to reform and accelerate the drug discovery and development process.

As LLS’s impact grows we see our important work not just helping patients with blood cancers, but reaching well beyond to help patients with other cancers and serious diseases as well. Treatments originally designed and tested in blood cancer patients are now being tested in other patients with diseases as diverse as pancreatic cancer and Parkinson’s disease. We have made much progress, but there is more work to be done.

We are inspired every day by the researchers who are in a hurry to find cures, by thousands of volunteers across the country raising funds and supporting patients, by our dedicated staff across our 55 chapters on the frontlines with patients and families, and, most of all, by blood cancer patients waging heroic battles against these diseases. With your continued support, we will make someday today for more blood cancer patients and pave the way for treatments and cures across the cancer landscape.
THERAPY ACCELERATION PROGRAM
LLS celebrated milestones achieved by several partners in our Therapy Acceleration Program (TAP), and introduced two new companies into the TAP portfolio in Fiscal Year 2015. We supported a total of 24 TAP partnerships in Fiscal Year 2015.

UNIVERSITY OF MICHIGAN
A promising University of Michigan research project, supported through TAP and focused on developing new treatments for patients with a rare and lethal subtype of leukemia, received a significant boost from a licensing agreement with a new biotechnology company, Kura Oncology. LLS has been funding this work, led by Assistant Professor Jolanta Grembecka, PhD, in collaboration with Tomasz Cierpicki, PhD, at the University of Michigan, since 2009. The research aims to develop new treatments for patients with leukemia associated with abnormalities in the mixed lineage leukemia (MLL) gene. These patients have a very poor prognosis with current therapies.

CELATOR PHARMACEUTICALS
LLS has been supporting the development of Celator Pharmaceuticals’ CPX-351, a special formulation of two standard chemotherapy drugs, to treat patients with high-risk acute myeloid leukemia (AML). The therapy received a Fast Track Designation from the U.S. Food and Drug Administration, and interim data released from a Phase 3 clinical trial showed that CPX-351 performed better than standard therapy. LLS looks forward to seeing the overall survival data within the coming year.

ONCOPEP
LLS entered into a partnership with OncoPep to advance an experimental cancer vaccine that is designed to activate the immune system and control smoldering multiple myeloma (SMM), an asymptomatic stage of myeloma.

Advancing Innovation in Research

The LLS research agenda is focused on finding cures. LLS drives research in areas of unmet medical need.
The vaccine, PVX-410, was granted orphan drug designation by the U.S. Food and Drug Administration in 2013. LLS has committed to an equity investment of $690,000 in the effort. A Phase 1/2 clinical trial is currently under way.

**KITE PHARMA**

LLS and Kite Pharma entered into a partnership to support a clinical trial for KTE-C19, a CAR-T (chimeric antigen receptor) immunotherapy for the treatment of patients with refractory non-Hodgkin lymphoma (NHL). KTE-C19 is an investigational therapy that genetically modifies patients’ T cells to target a specific protein, CD19, on the cell surface of B-cell lymphomas and leukemias. Once activated, the T cells home in on and eliminate the cancer cells.

**LLS’S VENTURE PHILANTHROPY IN THE MEDIA**

LLS’s venture philanthropy leadership in the cancer space garnered significant visibility in the October 2014 issue of *Health Affairs*, a leading peer-reviewed journal on health policy, thought and research. The article, “New Players Join the Drug Development Game,” features our TAP prominently throughout.

In developing TAP, LLS recognized the need to take a more proactive role in order to accelerate the development of treatments and cures. The *Health Affairs* article noted that five of the small companies that LLS invested in later benefited from investment and licensing deals from large pharmaceutical companies.
LLS continued to lead the charge against acute myeloid leukemia (AML) in Fiscal Year 2015, with its groundbreaking harry T. Mangurian, Jr. Foundation Beat AML collaboration. LLS teamed up with Brian Druker, MD, and his research team at Oregon Health & Science University’s Knight Cancer Institute in 2013 to accelerate the development of treatments for patients with AML. The researchers are deploying cutting-edge technology to create a profile of genetic defects in AML cells, and testing different drugs and drug combinations to determine the most effective treatments based on individual patients’ particular genetic mutations. As we look to the next phase of the groundbreaking Beat AML initiative in the coming year, LLS anticipates that the innovative collaboration will prove to be a model for other cancer research and discovery programs. Generous donors have contributed more than $8 million to support this initiative, including more than $4 million from the harry T. Mangurian, Jr., Foundation and more than $300,000 raised through an online spring campaign.

**THE EMPEROR OF ALL MALADIES**

LLS was a proud supporter of the PBS documentary, *Ken Burns Presents “Cancer: The Emperor of All Maladies,”* a film by Barak Goodman. The film showcased a number of key treatment advances pioneered by LLS, including groundbreaking work in targeted therapies for certain forms of leukemia. This brilliant history of cancer, based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, is really the story of LLS and blood cancers, and shows we are truly at a unique moment in our ability to treat and cure patients.

**AMERICAN SOCIETY OF HEMATOLOGY**

At the 56th American Society of Hematology (ASH) annual meeting, more than 20,000 researchers from around the world converged in San Francisco to learn about the latest exciting advances in treating blood cancers. The LLS-funded team from University of Pennsylvania...
The Leukemia & Lymphoma Society and The Children’s Hospital of Philadelphia continued to demonstrate more evidence of the durability of chimeric antigen receptor T-cell (CAR-T) immunotherapy for patients with acute lymphoblastic leukemia (ALL).

During the treatment, the patient’s immune T cells are engineered and then injected back into the patient to hunt and destroy cancer cells. After receiving the experimental treatment, 36 of 39 children (92%) with treatment-resistant ALL achieved a complete response. Six months after treatment, more than two-thirds (70%) of children enrolled in the study remained cancer free, and 75% have survived. Only five children have required subsequent treatment. The CAR-T approach, first pioneered in the blood cancers, is now being tested in other types of cancers, including breast, colon and pancreatic cancer and mesothelioma.

Other therapies showing promise are for patients with relapsed Hodgkin lymphoma (HL) and AML. The data with immune checkpoint inhibitors showed encouraging outcomes for patients with relapsed HL, which typically has a very poor prognosis. LLS is supporting this research as well.

An experimental approach to a therapy called IDH inhibitors showed promising, durable responses in patients with a subset of AML. This is encouraging news for a disease that has not seen a change in the standard of therapy in the past 40 years. Researchers reported response rates of between 50% and 60% in refractory AML patients.

In addition, two research teams, one from Italy and one from the U.S., both supported by LLS, reported a high response rate in two separate studies of a precision medicine approach to treating patients diagnosed with hairy cell leukemia. Patients in both trials were treated with vemurafenib, a therapy that inhibits the BRAF gene mutation present in 95% of these patients.

LLS’s Satellite Symposium at ASH
LLS featured immunotherapy at its satellite symposium in advance of the 56th ASH Annual Meeting. The symposium, “Emerging Immunotherapies for Hematologic Malignancies: Improving Patient Outcomes by Harnessing the Immune System,” featured renowned researchers and highlighted multiple approaches to stimulating the body’s immune system to kill cancer cells. The standing-room-only crowd of more than 700 attendees was evidence of the overwhelming interest in this subject.

Blood Cancer Drug Approvals in Fiscal Year 2015
Ibrutinib for Waldenstrom’s Macroglobulinemia
Breaking new ground, the U.S. Food and Drug Administration’s approval of ibrutinib (Imbruvica®) for all patients with Waldenstrom’s macroglobulinemia (WM) marked the first time a therapy was indicated specifically for patients with this rare diagnosis. Despite the numerous
currently utilized therapies to treat WM, until now there has been no standard of care for the disease and the current treatments are not curative. The approval of ibrutinib, which is given as an oral pill, as both a first-line therapy and for those who have relapsed after other therapies, is a promising development, as recurrence is common. Ibrutinib had been approved for patients with CLL and mantle cell lymphoma the previous year, and is now being tested for patients with pancreatic cancer.

**Idelalisib approved for CLL** The U.S. Food and Drug Administration’s approval of idelalisib to treat patients with relapsed CLL, follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) was a significant advance for patients, as the number of treatment options for patients continues to expand.

Idelalisib, an oral therapy indicated in combination with rituximab, is a first-in-class inhibitor of PI3K delta, a protein that is highly expressed in many B-cell malignancies and plays a critical role in the proliferation of these cancer cells. LLS-funded research helped pave the way to such inhibitors of the PI3K pathway. In another example of how blood cancer research continues to lead the way for other cancers, other PI3K inhibitors are also being tested for the treatment of patients with solid tumors.

**DANA-FARBER CELEBRATES 40 YEARS/$60M INVESTMENT** Dana-Farber Cancer Institute recognized LLS’s $60 million investment in its blood cancer research programs over 40 years at a special event in April. At the event, some of the world’s most accomplished physicians and scientists said that LLS’s investment in their work from the earliest days of their careers through the present allowed them to pursue with success areas of research for which they might not otherwise have had the resources.

**Conducted**

**6,000 clinical trial searches for patients in FY15**
Driving Policy Agenda: Federal and State Priorities

LLS recognizes that finding cures is not enough; we must ensure that patients have access to the treatments they need to live longer, better, healthier lives. LLS’s Policy and Advocacy Team is dedicated to removing barriers to care.

**ORAL PARITY BILLS**

There are now 40 states with oral parity legislation on the books. Since 2012, LLS has helped to pass “oral parity” legislation in 20 of these states, removing barriers for patients who rely on prescription drugs to treat their cancer. LLS played a role in helping bills get passed in 5 states this past year alone: North Dakota, South Dakota, Mississippi, Wyoming, and West Virginia.

**21ST CENTURY CURES**

LLS worked with Congress over the past year to help lawmakers develop the 21st Century Cures bill, a bipartisan Congressional initiative to invest in medical research and remove outdated impediments that slow the discovery and development of new therapies. In addition to LLS President and CEO Louis J. DeGennaro’s testimony during a House committee roundtable on personalized medicine, LLS advocates engaged their elected officials in Washington, D.C., and in their home states. The House approved the act with an overwhelming majority in July. Similar legislation is now being developed in the Senate for consideration this coming year.

**MILLIMAN REPORT AND OUT-OF-POCKET COSTS FOR PATIENTS**

LLS commissioned a study from Milliman Inc., which found that placing limits on out-of-pocket costs for patients would relieve their financial burden without imposing a significant impact on insurers. The study, which used examples of insurance plans available on health insurance exchanges across the country established by the Affordable Care Act, reinforces LLS’s efforts to advocate for state and federal legislation that helps to control patient out-of-pocket costs.

*LLS advocacy leaders came to D.C. and helped the 21st Century Cures Act pass in the House*
CO-PAY ASSISTANCE
LLS’s Co-Pay Assistance Program helps eligible patients with qualifying diagnoses pay their insurance premiums and meet co-pay obligations. LLS provided $41.8 million for patients in Fiscal Year 2015 to help them afford these costs.

PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM
The Patti Robinson Kaufmann First Connection Program is a peer-to-peer program that matches newly diagnosed patients and their families with trained volunteers who have been touched firsthand by a blood cancer and share similar experiences. In Fiscal Year 2015, the free service matched well over 1,000 patients with trained volunteers.

INFORMATION RESOURCE CENTER
LLS’s Information Resource Center (IRC) is a toll-free call center staffed by master’s level healthcare professionals equipped with the latest information on all of the blood cancers. IRC specialists responded to approximately 60,000 inquiries in Fiscal Year 2015, more than half related to financial hardship. Information specialists can be reached at (800) 955-4572 from 9 a.m. to 9 p.m. ET Monday through Friday.

Helping Patients Gain Access to Care
LLS is the leading source of free, highly specialized blood cancer information, education and support for patients, survivors, families and healthcare professionals.
Advancing Innovation in Fundraising

As a nonprofit, LLS relies on the generosity of individuals, corporations and foundations.

LIGHT THE NIGHT WELCOMES CHARLES ESTEN AS AMBASSADOR

In Fall 2014, friends, families and companies walked in LLS’s Light The Night® Walks in approximately 180 venues around the country, and raised $58.6 million to support LLS’s mission. Actor and musician Charles Esten joined LLS as the National Light The Night Walk honorary chair. Thankful for his daughter Addie’s recovery from childhood leukemia, Esten aimed to inspire other individuals, families and teams with his and Addie’s appearances in national public service announcements, radio segments and extensive educational materials promoting the Light The Night campaign. The Esten family also participated in the Light The Night Walk in their hometown of Nashville. Addie is living proof of LLS’s impact on blood cancer patients and their families. Her experience demonstrates that funds raised for research can result in lifesaving treatments and cures.

LIGHT THE NIGHT WALK / BURLINGTON

Burlington Stores has been supporting LLS’s Light The Night Walk campaign for the past 13 years. And in Fall 2014, for the 11th consecutive year, Burlington Stores was the largest national partner for Light The Night Walk. With a 15-week, in-store promotion, Burlington raised more than $3 million. Since the partnership began, Burlington, a national off-price retailer, has collected more than $22 million to help LLS advance therapies for blood cancer research and ensure patients have access to lifesaving treatments.

LEUKEMIA CUP REGATTA AND TIMEX

In Fiscal Year 2015, sailing enthusiasts who participated in LLS’s Leukemia Cup Regatta raised nearly $3.8 million for the LLS mission, culminating with a Fantasy Sail with Gary Jobson to take place in Bermuda in October 2015. Timex, the world’s leading global watch manufacturer, joined LLS as a national sponsor of the Leukemia Cup Regatta. Throughout calendar year 2015, Timex had a presence at events in support of LLS in the fight against cancer. The company also donated to LLS a percentage of the sales of its Yacht Racer watch.
TEAM IN TRAINING
Team In Training® (TNT) continues to deliver a meaningful fundraising and training experience to individuals who have a desire to move the LLS mission forward. In Fiscal Year 2015, more than 12,500 TNT participants came together to raise $41.8 million to support blood cancer research and patient services. TNT means corporate teams, community teams, passionate athletes, dedicated mission-minded fundraisers, online and social teams and more under one big TNT tent. The $1.4 billion dollars raised by TNT participants over 27 years has helped drive blood cancer survival rates to new heights. Go TEAM!

STUDENT SERIES
In Fiscal Year 2015, the combined Student Series (formerly known as School & Youth Programs) Pennies for Patients and Pasta for Pennies presented by Olive Garden raised a total of $27.7 million. Nearly 14.5 million students in 28,000 schools learned about service, leadership and philanthropy, and saw firsthand how their involvement made a difference in helping save the lives of blood cancer patients.

MAN & WOMAN OF THE YEAR
The 2015 Man & Woman of the Year campaign broke yet another record, with candidates raising more than $32.5 million to help end blood cancer. In the 25th year of this prestigious program, more than 900 participants from across the country competed for the coveted national title. Man of the Year Jason Fleischer of New York used creative techniques such as a cornhole tournament and a date auction to raise $302,045. The Woman of the Year, Erin Ragsdale of Texas, used her personal connections to elicit large donations that propelled her to a record-setting $469,159. Campaign donations totaled $1.7 million more than the previous year.

We also recognized our “All Star” alumni this year. This year the “All Star” winners were Summer Hall, from Davidson, NC, and Gary Cohen, from Hillsdale, NJ. Hall is a longtime LLS volunteer and mother who raised an “All Star” record of $167,000 for a world without blood cancers. Gary Cohen, a TNT alumnus, raised $62,335 to help eradicate blood cancers worldwide.
MAN & WOMAN OF THE YEAR WINNERS
JASON FLEISHER
AND ERIN RAGSDALE
**ONLINE FUNDRAISING AND LAUNCH OF NEW WEBSITE**

Charitable giving continued its migration online during Fiscal Year 2015, growing by 9% as compared to an industry overall growth rate of 2%. LLS was well ahead of that trend, with online donations growing 22% year over year, as we focused our digital strategy on streamlining our digital donation path and adapting our platforms to increasingly mobile-focused consumer behavior.

LLS.org relaunched in May with a new design and new technology that allows patients, professionals and supporters easier access to the wealth of content and support offered, whether they’re working at their desk, or have just left their doctor’s office and are urgently seeking information on their mobile phone.

The new site has improved functionality and clearer navigation to discussion, support and research pages. Visitors also see stories and photos of survivors, caregivers and volunteers, and have a chance to submit their own. The migration of all our campaign sites to a similar platform is under way and will be complete by the middle of our next fiscal year.

**BLOOD CANCER AWARENESS MONTH**

During Blood Cancer Awareness Month, LLS continued to ramp up its efforts to reach new audiences of participants and donors, as well as patients. The integrated marketing and communications campaign, featuring LLS President and CEO Louis J. DeGennaro, launched across TV, radio and digital channels, including our website, and created the strongest awareness yet for LLS. Our targeted call to action garnered donations of $433,000 through our website.
UNITED FOOD AND COMMERCIAL WORKERS UNION (UFCW)

The UFCW continued to grow its 32-year partnership with LLS, by connecting its Locals to our chapters in 20 markets to support LLS’s Light The Night Walk. It was a banner year for the UFCW’s commitment to LLS with an astounding $4,350,000 raised through Light The Night and the myriad other fundraising events the union holds to benefit LLS, including golf tournaments, dinners, auctions, clay shoots and more. UFCW members affiliated with The Beer Store supported a bottle drive for LLSC in Ontario. This initiative alone raised more than $1.7 million.

The UFCW has raised close to $77 million since 1983, and all funds raised by its more than 120 Locals in the U.S. and Canada are restricted to fund lifesaving research.

We salute new UFCW President Marc Perrone and the more than 1.3 million UFCW members for their tireless support and extraordinary commitment.

DONOR DEVELOPMENT – FUNDING THE MISSION

Donors were exceptionally generous with direct gifts of $27.9 million. A highlight was the completion of the $8.3 million fundraising campaign to Beat AML. This pioneering effort was sparked by a lead gift of $4 million from the Harry T. Mangurian, Jr. Foundation, and further advanced by long-time LLS volunteer Michael Copley, who served as National Chair. Under his leadership, generous donors across the country recognized the value of this effort and brought us to the fundraising finish line in two years, a full year earlier than expected.

Major Gift donors of $10,000 or more, who are listed in the pages of this report, funded many other mission-critical programs, ranging from new research in pediatric blood cancers to patient support through a Transportation Assistance Fund. And forward-looking individuals who chose to shape the future through their estate plans provided $10.2 million in resources this year with thoughtful bequests.
RESEARCH GRANTS

SPECIALIZED CENTER OF RESEARCH
The Specialized Center of Research Program funds multi-disciplinary research by teams of leading-edge academic investigators that hasten the discovery and development of better treatments for leukemia, lymphoma and myeloma patients. A center is composed of at least three independent research programs that are integrated and supported by scientific core laboratories.

Jerry Adams, PhD 2013
Walter & Eliza Hall Institute of Medical Research
Frederick Alt, PhD 2012
Immune Disease Institute
Jon Aster, MD 2013
Brigham and Women’s Hospital
John Byrd, MD 2011
The Ohio State University
William Carroll, MD 2014
New York University School of Medicine
Irene Ghobrial, MD 2014
Dana-Farber Cancer Institute
Anthony Green, MD, PhD 2012
University of California, San Francisco

CAREER DEVELOPMENT PROGRAM (SCHOLARS AND CLINICAL SCHOLARS)
The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

Gregory Abel, MD 2013
Dana-Farber Cancer Institute
K Mark Ansel, PhD 2013
University of California, San Francisco
Uttiya Basu, PhD 2016
Columbia University Medical Center
Julie Blander, PhD 2013
Imperial College School of Medicine at Mount Sinai
Ivan Borrello, MD 2008
The Johns Hopkins University School of Medicine
Patrick Brown, MD 2012
Icahn School of Medicine at Mount Sinai
Jan Burger, MD, PhD 2014
The University of Texas MD Anderson Cancer Center
George Calin, MD 2012
The University of Texas MD Anderson Cancer Center
Fernando Camargo, PhD 2016
Boston Children’s Hospital
lain Cheeseman, PhD 2013
Whitehead Institute for Biomedical Research
Dipanjnan Chowdhury, PhD 2015
Dana-Farber Cancer Institute
Christopher Cogle, MD 2013
University of Florida
Yali Dou, PhD 2013
University of Michigan
Benjamin Ebert, MD, PhD 2013
Brigham and Women's Hospital
Thomas Fazzio, PhD 2015
University of Massachusetts Medical School
Elsa Flores, PhD 2012
The University of Texas MD Anderson Cancer Center
Benjamin Garcia, PhD 2016
Perelman School of Medicine at the University of Pennsylvania
Ramiro Garzon, MD 2016
The Ohio State University
Andrei Goga, MD, PhD 2013
University of California, San Francisco
Ananda Goldrath, PhD 2012
University of California, San Diego
Jolanta Grembecka, PhD 2014
University of Michigan
David Guertin, PhD 2016
University of Massachusetts Medical School
Jonathan Higgins, PhD 2012
Newcastle University
Morgan Huse, PhD 2015
Memorial Sloan Kettering Cancer Center
Holbrook Kohrt, MD, PhD 2015
The Board of Trustees of the Leland Stanford Junior University
Marina Konopleva, MD, PhD 2012
The University of Texas MD Anderson Cancer Center

John Koreth, MD, PhD 2014
Dana-Farber Cancer Institute
Ross Levine, MD 2013
Memorial Sloan Kettering Cancer Center
Ming Li, PhD 2015
Memorial Sloan Kettering Cancer Center
Ivan Maillard, MD, PhD 2014
University of Michigan
Ravindra Majeti, MD, PhD 2016
The Board of Trustees of the Leland Stanford Junior University
Sami Malek, MD 2012
University of Michigan
Hanna Mikkola, MD, PhD 2012
University of California, Los Angeles
Golam Mohi, PhD 2014
SUNY Upstate Medical Center
James Mulloy, PhD 2011
Cincinnati Children’s Hospital Medical Center
Ryma Ohi, PhD 2014
Vanderbilt University Medical Center
Sophie Pazcesny, MD, PhD 2015
Indiana University
Emmanuel Passegué, PhD 2013
University of California, San Francisco
Cathie Pfleger, PhD 2013
Icahn School of Medicine at Mount Sinai
Joel Pomerantz, PhD 2012
Icahn School of Medicine at Mount Sinai

Talya Salz, PhD 2014
Memorial Sloan Kettering Cancer Center
Joseph Scandura, MD, PhD 2014
Well Cornell Medical College
Tait Shanafelt, MD 2013
Mayo Clinic
Jane Skok, PhD 2011
New York University School of Medicine of Medical Research
Ravindra Majeti, MD, PhD 2016
University of Massachusetts Medical School
Daniel Starczynowski, PhD 2016
Cincinnati Children’s Hospital Medical Center
Kimberly Stegmaier, MD 2014
Dana-Farber Cancer Institute
Ulrich Steidl, MD, PhD 2015
Albert Einstein College of Medicine
Enrico Tiacci, MD, PhD 2014
University of Perugia
Raoul Tibes, MD, PhD 2015
Mayo Clinic Arizona
Wei Tong, PhD 2014
The Children’s Hospital of Philadelphia
David Traver, PhD 2013
University of California, San Diego
Christopher Vakoc, MD, PhD 2016
Cold Spring Harbor Laboratory
Amit Verma, MD 2013
Albert Einstein College of Medicine of Yeshiva University
Loren Walensky, MD, PhD 2015
Dana-Farber Cancer Institute
Roland Walter, MD, PhD, MS 2015
Fred Hutchinson Cancer Research Center
Matthew Walter, MD 2014
Washington University School of Medicine in St. Louis
Hengbin Wang, PhD 2013
The University of Alabama at Birmingham
Wenyi Wei, PhD 2014
Beth Israel Deaconess Medical Center
David Weinstock, MD 2014
Dana-Farber Cancer Institute
Hans-Guido Wendel, MD 2015
Memorial Sloan Kettering Cancer Center
Johnathan Whetstone, PhD 2015
Massachusetts General Hospital
Catherine Wu, MD 2015
Dana-Farber Cancer Institute
Xiaochun Yu, MD, PhD 2015
University of Michigan
Shan Zha, MD, PhD 2014
Columbia University Medical Center
Chengcheng Zhang, PhD 2014
UT Southwestern Medical Center
Jing Zhang, PhD 2014
University of Wisconsin-Madison
Xiaolan Zhao, PhD 2014
Memorial Sloan Kettering Cancer Center
Lee Zou, PhD 2012
Massachusetts General Hospital
Elina Zuniga, PhD 2013
University of California, San Diego

1 Dr. John Byrd is funded in part by Rita Cavanaugh & Gerald Kafka, Phyllis & Douglas A. Smith, and Judy & Michael H. Thomas.
2 Dr. William Carroll is funded in part by Jane Elissa/Charlotte Meyers Endowment Fund.
3 Dr. Carl June is funded in part by the Edwards P. Evans Foundation.
4 Dr. Helen Heslop is funded in part by Lee Goodwin & Linda Schwartzstein.
5 Dr. Thomas Kippis is funded in part by Harvey & Yetta Saltzman.
6 Dr. Ivan Borrello is funded in part by Harry & Marilyn Goldstein.
7 Dr. Patrick Brown is fully funded by The Okawara Foundation.
8 Dr. Jolanta Grembecka is funded in part by Jennifer & Jeff Butler.
9 Dr. Hanna Mikkola is funded in part by Parents Against Leukemia.
10 Dr. Holbrook Kohrt is funded in part by The Marge & Charles J. Schott Foundation and the Cincinnati Golfers for Charity.
11 Dr. James Mulloy is funded in part by an anonymous donor.
12 Dr. Loredana Ruggieri is funded in part by an anonymous donor.
RESEARCH GRANTS (CONTINUED)

CAREER DEVELOPMENT PROGRAM (SPECIAL FELLOWS, CLINICAL SPECIAL FELLOWS, AND FELLOWS)

Alison Adams, PhD 2014
Yale University

Koshi Akahane, MD, PhD 2014
Dana-Farber Cancer Institute

Spencer Alford, PhD 2015
The Board of Trustees of the Leland Stanford Junior University

Burton Barnett, PhD 2015
University of California, San Diego

Cora Bergantinos, PhD 2015
Columbia University Medical Center

Ani Bhatt, MD, PhD 2014
Dana-Farber Cancer Institute

Jessica Blackburn, PhD 2014
Dana-Farber Cancer Institute

Ami Bhatt, MD, PhD 2014
Columbia University Medical Center

Spencer Alford, PhD 2015
The Board of Trustees of the Leland Stanford Junior University

Caron Jacobson, MD 2014
Cancer Center

Nicholas Brown, PhD 2016*
St. Jude Children’s Research Hospital

Marcella Cesana, PhD 2015
Boston Children’s Hospital

Tiffany Chang, MD 2014
University of California, San Francisco

Michael Chu, MD 2015
The Board of Trustees of the Leland Stanford Junior University

Annet Coskun, PhD 2016*
California Institute of Technology

Dan Dominissini, PhD 2016*
The University of Chicago

Zhixun Dou, PhD 2015
University of Pennsylvania

Jonathan Driver, PhD 2014
University of Washington

Changir Duy, PhD 2015 12
Weill Cornell Medical College

Chen Fang, PhD 2014 12
Fred Hutchinson Cancer Research Center

Eva Fast, PhD 2015
President & Fellows of Harvard College

Craig Forester, MD 2016*
University of California, San Francisco

Xiaofei Gao, PhD 2014
Whitehead Institute for Biomedical Research

Jacqueline Garcia, MD 2015
Dana-Farber Cancer Institute

Charles Gawad, MD 2014 21
The Board of Trustees of the Leland Stanford Junior University

Luke Gilbert, PhD 2014
University of California, San Francisco

Stephanie Grainger, PhD 2015
University of Pennsylvania

Sarah Hainer, PhD 2014
University of Massachusetts Medical School

Alexandre Iannello, PhD 2014
University of California, Berkeley

Andrew Intekofor, MD 2016*
Memorial Sloan Kettering Cancer Center

Caron Jacobson, MD 2014
Dana-Farber Cancer Institute

Ana Janic, PhD 2014
Walter & Eliza Hall Institute of Medical Research

Stephanie Johnson, PhD 2015
University of California, San Francisco

Brian Jonas, MD, PhD 2013
The Board of Trustees of the Leland Stanford Junior University

Neeraj Joshi, PhD 2016*
University of California, San Francisco

Christopher Kanakry, MD 2014
Johns Hopkins University

Michael Khodadoust, MD, PhD 2015
The Board of Trustees of the Leland Stanford Junior University

Seoyoun Kim, PhD 2015
Memorial Sloan Kettering Cancer Center

Maria Kleppe, PhD 2014
Memorial Sloan Kettering Cancer Center

Latika Kohli, PhD 2015
University of California, San Francisco

Andrew Lane, MD, PhD 2013
Dana-Farber Cancer Institute

I-Ju Lee, PhD 2016*
Dana-Farber Cancer Institute

Qiming Liang, PhD 2016*
University of Southern California

Xiangyu Liu, PhD 2014
Columbia University Medical Center

Michael Loftgren, PhD 2015
Harvard Medical School

Marko Lööke, PhD 2015
Massachusetts Institute of Technology

Siddhth Lu, PhD 2014
Boston Children’s Hospital

Zhuojuan Luo, PhD 2014
Northwestern University

Julia Maxson, PhD 2014
Fred Hutchinson Cancer Research Center

Jeffrey McKnight, PhD 2014
Fred Hutchinson Cancer Research Center

Marcellus Mues, PhD 2015
University of California, San Francisco

Vera Mugoni, PhD 2016*
Beth Israel Deaconess Medical Center

Jagan Muppudi, MD 2016*
University of California, San Francisco

Thang Nguyen, PhD 2014
California Institute of Technology

Kyla Omlusik, PhD 2013
University of California, San Diego

Ana Ortega Molina, PhD 2014
Memorial Sloan Kettering Cancer Center

Wen Pan, PhD 2015
Yale University

Lars Plate, PhD 2016*
The Scripps Research Institute

Heather Pua, MD 2015
The University of Utah

Kendra Sweet, MD 2014 23
H. Lee Moffitt Cancer Center & Research Institute

Sarwish Rafiq, PhD 2014 22
Memorial Sloan Kettering Cancer Center

Kausik Ragunathan, PhD 2014
Harvard Medical School

Parvathi Ranganathan, PhD 2014
The Ohio State University

John Reagan, MD 2014
Rhode Island Hospital

Justin Reitsma, PhD 2015
California Institute of Technology

Jessica Ridilla, PhD 2015
Brandeis University

Cory Rillahan, PhD 2015
Memorial Sloan Kettering Cancer Center

Prabhjot Sahani, PhD 2016*
Dana-Farber Cancer Institute

Amir Schajnovitz, PhD 2015
President & Fellows of Harvard College

Chao Yang, PhD 2016*
Icahn School of Medicine at Mount Sinai

Xiaoji Yu, PhD 2014
Boston Children’s Hospital

Heather Pua, MD, PhD 2014
Harvard Medical School

Joshua Zeidner, MD 2015
The University of North Carolina at Chapel Hill

Haoyuan Zhang, PhD 2014
Dana-Farber Cancer Institute

Yu Zhang, PhD 2015
Boston Children’s Hospital

Hufeng Zhou, PhD 2016*
Brigham and Women’s Hospital

12 Dr. Jane Skok is funded in part by The Jim Jacobs Charitable Foundation.
13 Dr. Loren Walensky is funded in part by Hockey Fights Cancer.
14 Dr. Tiffany Chang is funded in part by Cynthia Hinojosa and Sydney Tassin.
15 Dr. Charles Gwadz is funded in part by the Rally Foundation for Childhood Cancer Research.
16 Dr. Sarwish Rafiq is The Jake Wetchler Foundation Fellow of LLS.
17 Dr. Chen Fang is funded in part by the Melryder Foundation.
18 Dr. Kendra Sweet is funded in part by Imagine a Cure for Leukemia.
19 Newy awarded or renewed grants in fiscal year 2016
20 This program is run in partnership with the Myeloproliferative Neoplasm Research Foundation (MPNRF)
RESEARCH GRANTS (CONTINUED)

TRANSLATIONAL RESEARCH PROGRAM

The Translational Research Program supports outstanding investigations deemed by our expert advisors most likely to translate basic biomedical discoveries into new, safe and effective treatments, ultimately prolonging and enhancing patients’ lives.

Iannis Aifantis, PhD 2016
New York University School of Medicine

Gheath Al-Atrash DO, PhD 2015
The University of Texas MD Anderson Cancer Center

Caroline Arber, MD 2016*
MD Anderson Cancer Center

Ravi Bhatia, MD 2014
The University of Texas program

Lucio Castilla, PhD 2015
University of Massachusetts Medical School

Mukta Arora, MD 2014
Baylor College of Medicine

Leandro Cerchietti, MD 2016*
Weill Cornell Medical College

Curt Civin, MD 2014
University of Maryland, Baltimore

Xiao-bao Chang, PhD 2014
Mayo Clinic

Jianjun Chen, PhD 2014
University of Alabama at Twin Cities

Twin Cities

Robert Baiocchi, MD, PhD 2014
Beth Israel Deaconess Medical Center

Javeed Iqbal, PhD 2014
University of Nebraska Medical Center

Jolanta Grembecka, PhD 2016*
University of Minnesota, Twin Cities

Adolfo Ferrando, MD, PhD 2015
Cincinnati Children’s Hospital

Maria Figueroa, MD 2014
Weill Cornell Medical College

Maria Konopleva, PhD 2016*
Columbia University Medical Center

Douglas Graham, MD, PhD 2015
Cancer Center

Stephen Gottschalk, MD 2016*
Baylor College of Medicine

Bimalangshu Dey, MD, PhD 2014
B. Hilda Ye, PhD 2015

Stephen Forman, MD 2014
Beckman Research Institute of the City of Hope

Dean Lee, MD, PhD 2014
The University of Texas MD Anderson Cancer Center

Jianjun Chen, PhD 2014
The University of Chicago

Richard Jones, MD 2015
Weill Cornell Medical College

Karen Gaensler, MD 2014
University of California, San Francisco

Javi Pinilla, MD, PhD 2015
H. Lee Moffitt Cancer Center & Research Institute

Stephen Forman, MD 2014
Memorial Sloan Kettering Cancer Center

Karin Gaensler, MD 2014
University of Minnesota

Thomas Loughran, MD 2014
University of Virginia

Lucio Castilla, PhD 2015
San Francisco University of California, San Francisco

Javier Pinilla, MD, PhD 2015
University of Pennsylvania

John Kuruvilla, MD 2013
University of the City of Hope

Mignon Loh, MD 2015
University of Michigan

Stephen Gottschalk, MD 2016*
Baylor College of Medicine

Matthew Matasar, MD 2014
Memorial Sloan Kettering Cancer Center

Feuzy Rassool, PhD 2016
University of Pennsylvania

William Matsui, MD 2016*
Icahn School of Medicine at Mount Sinai

Feyruz Rassool, PhD 2016
University of California, San Francisco

Li Chai, MD 2016*
Weill Cornell Medical College

Steven Grant, MD 2015
Virginia Commonwealth University

Ila Melnick, MD 2014
Weill Cornell Medical College

Yi Chai, MD 2016*
Weill Cornell Medical College

H. Leighton Grimes, PhD 2013
University of Pennsylvania

Tarik Moroy, PhD 2015
Icahn School of Medicine at Mount Sinai

Robert Baicocci, MD, PhD 2014
The Ohio State University

Sanjeeve Dave, MD 2016*
Duke University Medical Center

Jolanta Grimes, PhD 2013
University of California, San Francisco

Ami Bais, PhD 2014*
Icahn School of Medicine at Mount Sinai

Robert Baiocchi, MD, PhD 2014
The Ohio State University

Vijay Paranandi, MD, PhD 2014
UT Southwestern Medical Center

Bimalangshu Dey, MD, PhD 2014
University of Nebraska Medical Center

Greg Lisciandrello, MD 2013
Cancer Center

Lucio Castilla, PhD 2015
San Francisco University of California, San Francisco

John Kuruvilla, MD 2013
University Health Network

John Kuruvilla, MD 2013
University of the City of Hope

Dean Lee, MD, PhD 2014
The University of Texas MD Anderson Cancer Center

Mignon Loh, MD 2015
University of Michigan

Iannis Aifantis, PhD 2016*
University of Montreal

Lucio Castilla, PhD 2015
University of Massachusetts Medical School

Leandro Cerchietti, MD 2016*
Weill Cornell Medical College

Li Chai, MD 2016*
Brigham and Women’s Hospital

Xiao-bao Chang, PhD 2014
Mayo Clinic

Jianjun Chen, PhD 2014
University of Chicago

Dean Lee, MD, PhD 2014
The University of Texas MD Anderson Cancer Center

Ross Levine, MD 2013
The University of Texas MD Anderson Cancer Center

Mignon Loh, MD 2015
University of California, San Francisco

Thomas Loughran, MD 2014
University of Virginia

Ivan Maillard, MD 2015
University of Michigan

Matthew Matasar, MD 2014
Memorial Sloan Kettering Cancer Center

William Matsui, MD 2016*
Icahn School of Medicine at Mount Sinai

Feuy Rassool, PhD 2016
University of California, San Francisco

Maria Figueroa, MD 2014
Weill Cornell Medical College

Rudi Fasan, PhD 2014
University of Rochester

Adolfo Ferrando, MD, PhD 2015
Columbia University Medical Center

María Figueroa, MD 2014
Weill Cornell Medical College

Andrew Kung, MD, PhD 2015
Columbia University Medical Center

24 Dr. Curt Civin is funded in part by Northrop Grumman.
25 Dr. Stephen Forman is funded in part by The Jim Jacobs Charitable Foundation.
26 Dr. Curt Civin is funded in part by The Jim Jacobs Charitable Foundation.
27 Dr. H. Leighton Grimes is funded in part by The Marge & Charles J. Schott Foundation and the Cincinnati Golfers for Charity.
28 Dr. John Kuruvilla is funded in part by Drive For a Cure.
29 Dr. Ross Levine is fully funded by The Edward P. Evans Foundation.
30 Dr. Andie Thomas-Tikhonenko, PhD 2016*
31 Dr. Markus Muschen is funded in part by an anonymous donor.
32 Dr. Javier Pinilla is funded in part by Imagine a Cure for Leukemia.
RESEARCH PORTFOLIOS

LLS Research Portfolios are groups of research projects organized around a specific blood cancer interest. The list below includes donors that generously invested in a specific LLS research portfolio during this fiscal year.

Accurate Diagnosis Project is funded in part by Nonnie Barbey and John Sullivan, John and Frances Beck Family Foundation, BD, Genentech and Robert Rosen.

Acute Lymphoblastic Leukemia Research Portfolio is funded in part by Samantha and Timothy Durst and Anonymous.

Acute Myeloid Leukemia and Myelodysplastic Syndromes Research Portfolio is funded in part by The Hildegarde D. Becher Foundation, Inc.

Chronic Lymphocytic Leukemia Research Portfolio is funded in part by Stephen and Madeline Arnbinder, Deborah and Randy Daniels, George L. Shields Foundation, Tom Hancock, the Lasser Next Generation Fund, Anonymous.

Chronic Myelogenous Leukemia Research Portfolio is funded in part by Abbeville Family Partnership, Charles Foundation, Rebecca Godchaux, Larry and Leslie Nance.

Follicular Lymphoma Research Portfolio is funded in part by Beth Salter.


Screen to Lead Program is funded in part by Claire Fair.


Therapy Acceleration Program is funded in part by Baltimore Tour de Court – in Memory of Rachel Minkove and Seattle Genetics and Team Natasha.

Immunotherapy Research Portfolio is funded in part by Sammons Enterprises.

Myeloma and Waldenstrom Macroglobulinemia Research Portfolio is funded in part by Access Capital Foundation and The Shimkin Foundation.

Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by Douglas Baughman, Lisa and Craig Hawkins, and Debbie and Danny McQuary.


Quality of Life Research Portfolio is funded in part by Escher Foundation, The Hamill Family Trust, and Hildegarde D. Becher Foundation, Inc.

Targeted Therapies is funded in part by Claire Fair.


Hodgkin Lymphoma Research Portfolio is funded in part by Baltimore Tour de Court – in Memory of Rachel Minkove and Seattle Genetics and Team Natasha.

Immunotherapy Research Portfolio is funded in part by Sammons Enterprises.

Myeloma and Waldenstrom Macroglobulinemia Research Portfolio is funded in part by Access Capital Foundation and The Shimkin Foundation.

Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by Douglas Baughman, Lisa and Craig Hawkins, and Debbie and Danny McQuary.


Quality of Life Research Portfolio is funded in part by Escher Foundation, The Hamill Family Trust, and Hildegarde D. Becher Foundation, Inc.

Targeted Therapies is funded in part by Claire Fair.


Hodgkin Lymphoma Research Portfolio is funded in part by Baltimore Tour de Court – in Memory of Rachel Minkove and Seattle Genetics and Team Natasha.

Immunotherapy Research Portfolio is funded in part by Sammons Enterprises.

Myeloma and Waldenstrom Macroglobulinemia Research Portfolio is funded in part by Access Capital Foundation and The Shimkin Foundation.

Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by Douglas Baughman, Lisa and Craig Hawkins, and Debbie and Danny McQuary.


Quality of Life Research Portfolio is funded in part by Escher Foundation, The Hamill Family Trust, and Hildegarde D. Becher Foundation, Inc.

Targeted Therapies is funded in part by Claire Fair.

**ENDOWMENT FUNDS**

The Bill Beattie Memorial Endowment Fund (Alberta)
de Villiers Endowment Fund
GlaxoSmithKline Foundation – Gertrude B. Elion Endowment Fund
GlaxoSmithKline, Inc. Research Fund
Jane Elissa/Charlotte Meyers Endowment Fund
Jim Jacobs Leukemia Research Fund
Mary & Robert Bronstein Memorial Fund
The Rachel Kudish Fund
The Rae Endowment Fund (Ontario)
Reich Endowment Fund
Thomas M. Ford Memorial Fund
The Virginia Major Brooks Memorial Endowment Fund
Vrushali Ranadive Fellowship Fund
The UFCW (Canada) Endowment Fund

**PARTNERSHIPS**

**THERAPY ACCELERATION PROGRAM PARTNERSHIPS**

Acetylgon Pharmaceuticals, Inc. Boston, MA
Affimed Therapeutics AG, Heidelberg, Germany
arGEN-X BV, Breda, Netherlands
BioTheryX, Inc., Chappaqua, NY
Ivan Borrello, MD, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Celator Pharmaceuticals, Inc., Cambridge, MA
Christopher Cogle, MD, University of Florida
Constellation Pharmaceuticals, Inc., Cambridge, MA
Curis, Inc, Lexington, MA
Brian Druker, MD, Oregon Health & Science University
Mark Frattini, MD, PhD, Memorial Sloan Kettering Cancer Center
Irene Ghobrial, MD, Dana-Farber Cancer Institute
Jolanta Grembecka, PhD, University of Michigan
Anand Jillella, MD, Emory University
Kite Pharma, Inc., Santa Monica, CA
Holbrook Kohrt, MD, PhD, The Board of Trustees of the Leland Stanford Junior University
The Learning Collaborative, Kansas City, KS
Ron Levy, MD, The Board of Trustees of the Leland Stanford Junior University
OncoPep, Inc., North Andover, MA
Daniel Pollyea, MD, University of Colorado
Yogen Saunthararajah, MD, Cleveland Clinic
Stemline Therapeutics, Inc., New York, NY
Valo Biotherapeutics, LLC, Dallas, TX

**MEDICAL & SCIENTIFIC ADVISORS**

Steven Rosen, MD, FACP, Beckman Research Institute of City of Hope Chair
Stephen Ansell, MD, PhD, Mayo Clinic
Ravi Bhatia, MD, The University of Alabama at Birmingham
Alexandra Mayes Birnbaum, Peartree Communications, Inc.
James Bradner, MD, Dana-Farber Cancer Institute
Alan D’Andrea, MD, Dana-Farber Cancer Institute
Giulio Draetta, MD, PhD, The University of Texas MD Anderson Cancer Center
Philip Frost, MD, PhD, Opko Health, Inc.
Larry Kwak, MD, Beckman Research Institute of City of Hope
Michelle LeBeau, PhD, The University of Chicago
Ross Levine, MD, Memorial Sloan Kettering Cancer Center
Jonathan Licht, MD, Northwestern University
Alan List, MD, H. Lee Moffitt Cancer Center & Research Institute
Susan O’Brien, MD, University of California, Irvine
Franklin O. Smith, III, MD, Medpace

**THERAPY ACCELERATION PROGRAM ADVISORS**

Dana Callow, MBA, Boston Millennia Partners Chair
James Bradner, MD, Dana-Farber Cancer Institute
Joseph Catino, PhD, Retired from Bayer
C. Casey Cunningham, MD, Santé Ventures
William Dalton, MD, PhD, M2Gen
Ian W. Flinn, MD, PhD, Tennessee Oncology
Jennifer Gordon, PhD, JD, Paul, Weiss, Rifkind, Wharton & Garrison LLP
Ross Levine, MD, Memorial Sloan Kettering Cancer Center
Vern Norvie, JD, Wilson, Sonsini Goodrich & Rosati
Susan M. O’Brien, MD, University of California, Irvine
J. Fred Pritchard, PhD, Celerion
$250,000 – $499,999 (VISIONARY)

- BDO
- Carter’s Inc.
- Ebit Systems of America
- GEICO
- Global Franchise Group
- IHOP
- Elizabeth and Charles Jacobs
- Crisante and Timothy Lindfelter
- PwC
- Pfizer, Inc.
- Amanda and G. Brint Ryan
- Salesforce.com
- Silicon Valley Bank
- Stater Bros. Charities
- Kathryn and Leo Vecellio
- Walgreens
- Wells Fargo

$100,000 – $249,999 (PATRON)

- Alex and Ani
- Alto-Shaam, Inc.
- The Amgen Foundation
- Arthur J. Gallagher Foundation
- At Home
- Baker Botts LLP
- Dr. Evelyn Bata
- BB&T Bank
- The Blackstone Charitable Foundation
- BMC
- Boehringer Ingelheim
- Booz Allen Hamilton
- Peter and Janice Brock
- CA Technologies
- Cancer Treatment Centers of America
- Clyde S. McGregor & LeAnn Pederson Pope in Memory of Joan Knowing McGregor
- David Yurman
- Deloitte
- Discount Tire Co.
- F. M. Kirby Foundation
- FIS Foundation
- Fleming’s Prime Steakhouse & Wine Bar
- Florida Cancer Specialists & Research Institute
- Ethel and Bernard Garil
- Global Traveler Magazine
- GSP Transportation
- Hayes Family Fund
- HM Insurance Group
- Hospira Foundation
- Kat Hurd
- John and Kristin Hyland
- Incyte Corporation
- Industrial Alliance Insurance and Financial Services
- Neil and Emily Kiischer
- KPMG
- Lighthouse Investment Partners, LLC
- Paul Leinwand
- Jackson Lewis
- LLS New York City Chapter Board of Trustees
- The Marge & Charles J. Schott Foundation
- Mercedes-Benz USA, LLC
- Missouri Foundation for Health
- Northern California Cure-a-Thon
- Northrop Grumman
- Pamela B. Katten Memorial Leukemia Research Foundation
- PRIMA
- Donald Porteous
- Bonnie Magid Roditti
- Nancy C. and Richard Rogers
- Samuel Freeman Charitable Trust
- Seattle Genetics
- SMART Modular Technologies
- Spectrum Pharmaceuticals, Inc.
- Terumo BCT
- Vistar
- VITAS Innovative Hospice Care
- Waddell & Reed
- Western Reserve Restaurant Management Inc.
- Anonymous (1)

$50,000 – $99,999 (INNOVATOR)

- ABM Janitorial-Midwest
- Allegheny Foundation
- Allstate Insurance Company
- Alion 7-Eleven
- American Airlines
- American Systems
- Amgen
- Jean and C.E. Andrews
- Bank of America Merrill Lynch
- Nonnie and John Barbee
- BaubieBar
- Briggs Equipment
- Jaime Burgess
- Patrick Byrne
- Jessica and Kirk Cassidy
- Rita Cavanagh and Gerald Kafka
- C.H. Robinson Worldwide, Inc.
- C.J. Coakley Co., Inc.
- CareFirst BlueCross BlueShield
- The Charles Engelhard Foundation
- The Charles T. Bauer Charitable Foundation
- The Coleman Foundation, Inc.
- Comcast Spotlight
- Community Foundation
- Sonoma County
- Community Health Charities
- Dennis Crowley
- Matthew Dorsey
- Earl D. and Marian N. Olson Fund
- Enmark Stations, Inc.
- EZCorp
- For Julie Foundation, Inc.
- Kevin Fried
- Garden City Turkey Trot
- Dr. Frank and Dr. Jillian Glass
- Lee Goodwin and Linda Schwartzstein
- Andy Gordon
- The Hamill Family Trust
- Hargrove
- The Harry and Jeanette Weinberg Foundation, Inc.
- Allan Holt
- Infor
- J & J Development
- J & J Shared Services
- The Jake Wetchler Foundation
- Tony and Amie James
- Jazz Pharmaceuticals
- John and Frances Beck Family Foundation
- John Kellenyi
- K-Town Kickin for a Cure
- Kolache Factory
- Labors’ Charitable Foundation
- Melissa Leatherbury
- Lehig Valley Restaurant Group
- Red Robin
- Steven Lieblich
- Lilly
- Lundbeck Canada Inc.
- The Victor E. and Caroline E. Schutte Foundation
- The Walt Disney Company
- Washingtonian Magazine
- WAWA, Inc.
- The Whitney Foundation
- Richard G. Wilbur
- Anonymous (5)

$25,000 – $49,999 (ADVOCATE)

- 3 Sisters Ranch
- 21st Century Fox
- A.C.E. Family Foundation
- ADP
- Aetna
- Stephen and Madeline Anbinder
- Alvin M. Cornell Foundation
- Ameren
- American Family Care
- Amgen Oncology
- Annaly Capital Management
- Anthem Blue Cross & Blue Shield
- Aon Risk Solutions
- ARAMARK
- Assurant Specialty Property
- Astellas Pharma US, Inc.
- Axia Energy
- Baker Tilly
- Baltimore Tour de Cure
- In Memory of Rachel Minkove
- Baptist Health South Florida
- Douglas H. Baughman
- BBVA Compass
- Beach Body LLC
- Peggy Beckman
- Benevolence Community Impact Fund
- James Bennett
- Bert Smith & Co.
DONORS (CONTINUED)

Beyond The Rack
BJC Healthcare
Black Dog Charity
BMW Harris Bank
Bon Secours St. Francis Health System
Mel and Valerie Booth*
Boscow's
Braman Honda
Brayton Purcell, LLP
Morris and Pamela Brown
Joe and Cynthia Bruno*
John Bryant
Cardinal Solutions
The Caring Foundation
Carlos Batista Foundation
Carlson Family Foundation, Inc.
Mona Carlton and Grey Stogner
Michael W. Carraway
CBRE
CBRE – New England
CFACQ
Chambers Family Foundation
The Charter Foundation
Chiaramonte Construction Company
Cincinnati Golfers for Charity
Chiaramonte Construction
The Cottrell Foundation
Dr. Deirdre Cosby and Alisa Morgan
Communities Foundation of Texas
Comedy Central
Comcast
Comedy Central
Commerce Bank
Communities Foundation of Texas
Dr. Derridg Cosby and Alisa Morgan
The Cottrell Foundation
Crane Fund for Widows and Children
Dana-Farber Cancer Institute
Danford Foundation
David M. Polen Retirement Plan Trust
Diamond Wireless
DiBella's Old Fashioned
Submarines
Roland Dickson
Digitas Health LifeBrands
DLA Piper LLP
The Donald J. Trump Foundation, Inc.
Francis Dority and Margaret McGee
Marian Dozier
Driscoll's
Samantha and Timothy Durst* The Edgar A. Thomson Foundation
Faulkner Subaru
FBFR
Financial Recovery Strategies, First Business Bank
Florida Power & Light Company
Flushing Bank
Fox5
Franklin American Mortgage Company
Furniture Fair
G&I Orthopaedics and Sports Medicine
Generac Power Systems
General Dynamics Information Technology
John George
Gila River Casinos
Allan and Sherri Goldman
David Grais
Great American Insurance Group
HCA Foundation
Sera Hernandez
Andrew Herzog
Hewlett-Packard
Al G. Hill, Jr.
Highland Park Village
Hildgarde D. Becher
Hildegard D. Becher
Houghtlin Lawrence Real Estate
In Memory of Henry “Butch” Hubschman
Sharon Hunt
ICAP Services North America LLC
Independent Health
Industrial Alliance
Infinity Pharmaceuticals PS Insulators and Allied Workers International
Investors Group Financial Services Inc.
Hamilton E. James and Amie James
Janssen
Jewish Community Foundation of Cherry Hill
The Jim Jacobs Charitable Foundation
Steven and Ellen Jackson/ACI International
Jimmy Pappas Memorial Shoot
Susan Karches
K2 Intelligence, LLC
Kaiser Permanente
Kent's Run
King & Spalding LLP
The Kroger Foundation
Don C. & Diane S. Lake Family
Leon Medical Centers
Brian Levine
Al and Suzanne Lord
Las Vegas Metro Government
The Lottz Family Foundation
Lundard's Supermarket Inc.
Macquarie
Manatt, Phelps & Phillips, LLP
Marsh Supermarkets, Inc. (Corp)
Roxanne and Rocco Martino
MAXIMUS Foundation
Mayo Clinic
The McElrath Family Foundation
MB Financial
Medimmune, LLC
Merck
Michael C. Fina
Miles & Stockbridge
Morgan Stanley
The National Bank Of Georgia
New York Community Bank
North Bay Cancer Alliance
Norton Rose Fulbright
NPL Construction Company
Lynne and Greg O'Brien
Offshore Sailing School
The Otterfinger Family
OneSource Distributors
Patrick Park
Paul & Joan Rubschlager Foundation
Peoples Natural Gas
PEPCO
PFG / Vistar
PGT Trucking, Pat Gallagher
Philips-Van Heusen Foundation Inc.
Ping Y. Tai Foundation
Joel Plotkin
PNC Bank
Jenny Pruitt
Quintiles, Inc.
Rally Foundation for Childhood Cancer Research
Ray Catena Auto Group
Regions Financial Corporation
Resource America, Inc.
Rhusen Rock Hill Run & Ramble
Riemer & Braunstein LLP
Robert A. Rosania
ROMA Charitable Foundation
RPA Advisors, LLC
Jeff and Pat Sachs*
Jeffrey D. Sachs
SanDisk
Scott Savacool
Helena Scott
Rhonda and Bob Silver
Roger Staubach
Sephora
The Shinkin Foundation
The Smashburger Servicing Company LLC
Solutionreach, Inc.
St. Joseph’s/Candler
Stephen Birnbaum Foundation
Sunesis Pharmaceuticals, Inc.
Vivian Talavera
Tappan Zee Constructors, LLC
TD Bank
Terranea Resort
Tigerflight Foundation
Judy and Michael H. Thomas
Tucker Holmes, P.C.
UCFC Local 99
Ultimate Software
UPMC
Valenti Mid-Atlantic Management, LLC
Valero Energy Foundation
Vinson & Elkins LLP
Virginia Sheldon Jerome Foundation
Seth Vivek
The W. O'Neil Foundation
Scott Ward
Ellen Weissberg
WASHINGTON BUSINESS JOURNAL
Western Refining
Wet Willie's Management Corp.
William R. Rich Foundation
Woodmont High School
WTOP Radio
Zappos.com
Anonymous (2)

$10,000 – $24,999 (GIVING CIRCLE)

7 Eleven, Inc.
67 Whipsnany Constructor, LLC
225 Fourth LLC/Orda Management Corp
100 Club to Benefit Cancer, Inc.
Abacus Group, LLC
Abacus Technical Services, LLC
ABC 7/WJLA-TV
Abramson Cancer Center
Access Capital Foundation
Ace Parking*
ACHS Insurance Company
Acosta
The Advanci-Finch Fund
Ann Adams
Adler Realty
a/b Contract Furniture Inc.
Aero Administrative Service Corp.
Agios Pharmaceuticals
Ahern Family
Aidcr Company Limited
Air Products
Akin Gump Strauss Hauer & Feld LLP
Albert and Elaine Borchard Foundation
Albrecht Family Foundation
Alliance Data
Allianz Asset Management
Almond & Company, LLC
The Alpschul Foundation
American Punjabi Charity Golf Association
American CentFury Investments
American Direct Marketing Resources LLC
American Electric Power
American Expediting Company
Andarko Petroleum
Ann Taylor
The Anne & Henry Zarrow Foundation
Team Annie Rose Foundation
Ariad Pharmaceuticals, Inc.
Artel LLC
AstraZeneca
Augusta Oncology Associates
Auntie Lao’s Fan Club
Avalon Bay
Avela Specialty Pharmacy
Marla Avila
Bacardi USA
Michaeline and Brian Bahnisen
Bailey's Cancer Busters
Paul Baits
Jocelyn Ball
Banner MD Anderson Cancer Center
Banner University Medical Center
Mike and Joyce Barker
The Baratta Family Fund
The Barbara and William Rosenthal Family Foundation
Bartlett Coke General Contractors
BASF The Chemical Company
Lee Bates
Beacon Capital Partners
Beckman Coulter Foundation
Becky and Dana Callow Family
Ben Carter Enterprises
The Ben May Charitable Trust
Bender Foundation
Jorge Benitez
Les Bentley
The BEP Foundation
Bergen-Henry Associates
The Berghof/Boyle Foundation
Johanna Berkman and Manny Weintraub
Berksire Bank
The Bernal T. Chomeau Private Foundation
The Bernard McDonough Foundation
Peter and Barbara Bemnick
Robert Berry
Beta Engineering
Walt and Teri Bettinger
The Leukemia & Lymphoma Society

public policy
research
campaign
patient services

California Community Foundation
C. Jay Moorhead Foundation
Jennifer and Jeff Butler
Butler Family Foundation
Burns & McDonnell
Margot Burgwyn
Burgerfi International
The Bruning Foundation
Hutchins Family
The Bruce and Pricilla Foundation
Bruce Cohen Memorial Cancer Center
Howard Brown
B. Bruce Cohen Memorial Cancer Foundation
The Bruce and Pricilla
Hutchins Family
The Bruning Foundation
BTIG, LLC
Buchanan Ingersoll & Rooney PC
Jeff, Carol and Rebecca Burch
Burgerfi International
Margot Burgwyn
Burns & McDonnell
Butler Family Foundation
Jennifer and Jeff Butler
C. Jay Moorhead Foundation
Mary Cahill
California Community Foundation
Endowment Account
Cambia and Brian Reinsborough
Campbell & Brannon, LLC
CancerCare, Inc.©
Capital One Bank
Capitol Hospitality, LLC
Capstone Advisory Group, LLC
Carahsoft Technology
Caribe Concepts Co. LLP
Caribbean Property Group
Carnival Cruise
Carol Lavin Bernick Family Foundation
CarolinasHealthCare System
Michael Carr
Donald J. Carter
CBIZ MHM, LLC
Celator Pharmaceuticals
Centennial Technologies
Centimark
Century Voyager
Cerner Corporation
CertaPro
Chan Soon-Shiong Family Foundation
Charity Buzz
Charles Foundation and Becky Goddchaux
Chase Family Foundation
Mark S. Chehi
Chesney Miles Charitable Fund
Chick-fil-A
Chideo
Childrens Hospital & Medical Center
Deborah Christine
Christy Houston Foundation
Justine, Pauline, Aidan and Natalie Chuhe
Church & Dwight
CIESCO Inc.
CIGNA Foundation
Circle City Foundation
Cindy Citrone
Clark Construction Group, LLC
Elizabeth Clark
Jay and Susan Clark
Clune Construction Company
Cobalt Talon
Chris Coffin
The Cobb Foundation
CohnReznick
Color Me Rad
Comcast NBCUniversal
Community Blood Center/Community Tissue Services
Community Medical Centers
CONCACAF
Robyn and Don Conlon
Contemporary Electric Services, Inc.
Charles Cooper
Liz and Michael Copley
Cora & John H. Davis Foundation
Cordia Partners
The Cornell/Nicholson Team at UBS
Debra and Joseph Corrado
County of San Diego – Neighborhood Reinvestment Program
Courtney Knight Gaines Foundation
Coven Group, Inc.
Cox Family of Brownlee, SK Foundation
Crane Co.
Credit Suisse
Crop Production Services – Dean Albrecht
Cross Country Consulting
Crucon Cruise
Cruise Industry Charitable Foundation
CSL Behring Canada Inc.
Cubist Pharmaceuticals©
Timothy Curt
Cushman & Wakefield
CW & Dorothy G. Love Foundation
Ashley Dabbire
Dallas Auction Gallery
DanaHouse Corporation
Thuy and Mitch Dancik
Deborah and Randy Daniels
Dan's Supreme Super Markets
John Dauer
Donald W. Davis
James H. Davis, PhD, JD
Adrian De Brasi
The de Moya Group Inc.
Deans Knight Capital Management Ltd.
Dechert LLP
Ellen DeChristopher
Deltak
Joseph DeSacia
Deutsche Bank
Dickinson Fleet Services
Dillon Cameron
DIRECTV
Dittmar Company
Sean DiTullio
DLE Equipment
Dominion foundation
Dominos
Don Duet
Paul Dorman
Dr. Gerald and Paula McNichols Family Foundation
Tricia and Joel Drake
DreamWorks Animation
Dubose & Dorothy Heyward Memorial Fund
Tom Dunham
Dylan Perry Memorial
Golf Tournament
EagleBank
The Earl and Brenda Shapiro Foundation
Eckert Seamans Cherry & Mellott, LLC
Ed & H. Pillsbury Foundation
Edith M. Schweckendiek Trusts
EFESTE Winery
EJF Capital LLC
EKSAH
El Scorcho
Elap Services
Elizabeth Gracie/O'Keefe Lyons and Hynes
Elks of Los Angeles Foundation
Ellis & Ellis
EMC
Scott Emerson/The Emerson Group
The Employees of Maple Lodge Farms
EN Engineering
Energy Future Holdings
Entergy
Enchiridion Foundation
Entergy
Enterprise Holdings Foundation
DONORS (CONTINUED)

Foundation
GetWellNetwork, Inc.
Christos and Patricia Giannoulias
Giant Food
Giant Tiger Stores Limited
Peter and Ann Gilbert
Jill Gillette
Global Prairie
GM-AC
The Gold Law Firm
Goldman Sachs
Brad Goldstein & Lauren Clymer
Peter D. and Catherine D. Gordon
Gosling’s Rum
Granger
The Granger Foundation
Grand Finale Auction
Grange Insurance Companies
Jonathan Gray
Gray Line of San Francisco
Greater Kansas City Community Foundation
Greene Family Foundation
Greenberg Traurig
Hugo Gutierrez, Jr.
GZ Total Control, Inc.
Hadden Landscape, Inc.
Cory and Jennifer Hall
Leonard Halpern
Sheryl Hambidge
The Handley Foundation
Robin Harman
The Hartley Company
The Harvey E. Najim Family Foundation
Harv’s Car Wash
Diana Havercost
Lisa and Craig Hawkins
Karren Hays
HBS MNA 2015 Section A
Mark Heese
John Heimann
Kathleen Helge
The Helis Foundation
Heritage Title Company of Austin, Inc.
Rob Heyvaert
Marcy and Donnie Hill
Richard Hirayama
HireStrategy
HITT Contracting, Inc.
Rick Hoagland
Hogan Lovells Move
Daniel Hood
Albert Hopkins
Horizon Beverage Company, Inc.
HOT 99.5
Howard Family Foundation
Robert Howe
Hoxworth Blood Center
Tam and Dave Hubler
Huffington Foundation
Hunter’s Green Country Club
William Huntress
Huntsman LLC
Hy Vee, Inc.
IBC Bank
IBERIABANK
Ignition Footwear Company
Ilse Nelson Fund at New York Community Trust
IMS Health
Independence Blue Cross
Indianapolis Indians
Infinity Pharmaceuticals, Inc.
InfoReliance Corporation
Ingersoll Rand
InquisiT, LLC
Insulators International Health Hazard Fund
INTEC Group, Inc.
Intel Security
International Society, Herme deWyman Miro, President
Interplanetary Inc.
Investors Group Financial Services
ISC Sales LLC
David and Jill Israel/Sessions, Fishman, Nathan & Israel, LLC
Ivie and Associates
J.T. Tai & Co Foundation, Inc.
Jack Henry & Associates
David Jackson
The James Cancer Hospital/ Wexner Medical Center at The Ohio State University
James and Sunny Neff Foundation
Jane and Frances Stein Foundation
Janssen Ortho LLC
Brian Jaramillo
Jarden Westchester Tri
Jared Coones Pumpkin Run
JB Fuqua Foundation, Inc.
JDP Mechanical Inc.
Jim Koons Automotive
The Jim Quay Memorial Fund
Joan C. Ray Charitable Foundation
The John M. and Sally B. Thornton Foundation
John T. Gorman Foundation
The John Simpson Memorial Golf Outing
John Thurer Cancer Center
Johnson & Johnson Suncoast
Murray and Diana Johnson
Diane Johnston
Joseph R. Daly Foundation
Kent Joshi
Patrick Joyce
The June and Cecil Midole Charitable Fund
JP Morgan Chase
Susan and Daniel G. Kane
Kansa City Chiefs/Hunt Family Foundation
Raj and Vy Kapoor
Karing For Karley
In Memory of Betty Karpinski
Kasasa by BancVue
Kathryn Dent and John L. Tillman Charitable Fund
Stacey and David Kaufman
Michael Keating
KentuckyOne Health
The Kerins Family
Kids “R” Kids International, Inc.
Kiewit Companies Foundation
Kilroy’s Indy LLC
King Business Interiors
The Kirlin Group
Larry and Kim Kittoe
Chuck Kiven
Diana Knifer
Knowledge Services
Vickie Kontos
Korn Ferry
Thomas Koski
Josh Koanick
Charles F. Kriser
Kritchman Family Foundation
Kroger Community Rewards
Jules and Lynn Kroll
The Kroll Family Foundation
KST Data, Inc.
KU School of Pharmacy Student Organizations
The Lab World Group LLC
David Lacey
Ladish Co. Foundation
Michael Ladr
Diane Lake
John and Faye Lamb
Joni and Dave Lang
Lasser Next Generation Fund
Latham & Watkins LLP
The LaVerna Hahn Charitable Trust
William Lawlor
Ronal Lawson
Shea Lea
Michael Lebrun
Brian Lee
Left Hand Brewing Company
Leland Morris Family Foundation
Mashkin Foundation
Massapequa Turkey Trot
Massapequa Youth Lacrosse Club
Michael Maser
Kim and Matthew Mausser
Steve and Sherry Mayer*
Mayo Clinic Scottsdale
Mary Whelan Levine
Mary and Lawrence Liebscher
Connie Lindsey
The Lipman Family
James Lippman
Lisi
Kim and James R. Lites
Little Treasures Inc.
Brian Littleton
LMI
Lockheed Martin
Lockton Companies
Lord & Taylor
Hogan Lovells
Luken’s Fund
Luppe & Paula Luppen Family Foundation
M&T Bank
Mabee/Gumpert Philanthropic Fund
Matching Gifts
Tom Macek
Daran Machule
Mack Madness, Inc.
Macy’s
Macy’s/Bloomingdale’s
Magnolia Foundation
Magnum Power Products LLC
Robert Maher
Major Hyndai
Malacos Properties, LTD
Massachusetts General Hospital Cancer Center
Mansfield Jackie Mansfield
Marble Slab Creamery
Margaret and Donald Austin Family Foundation
Mariner Real Estate
Management, LLC
Mariner Wealth Advisors
Marylou’s Coffee
The Marksmen Company
Maslin
Foundation
Massapequa Turkey Trot
Massapequa Youth Lacrosse Club
Michael Maser
Kim and Matthew Mausser
Steve and Sherry Mayer*
Mayo Clinic Scottsdale
Mary Whelan Levine
Mary and Lawrence Liebscher
Connie Lindsey
The Lipman Family
James Lippman
Lisi
Kim and James R. Lites
Little Treasures Inc.
Brian Littleton
LMI
Lockheed Martin
Lockton Companies
Lord & Taylor
Hogan Lovells
Luken’s Fund
Luppe & Paula Luppen Family Foundation
M&T Bank
Mabee/Gumpert Philanthropic Fund
Matching Gifts
Tom Macek
Daran Machule
Mack Madness, Inc.
Macy’s
Macy’s/Bloomingdale’s
Magnolia Foundation
Magnum Power Products LLC
Robert Maher
Major Hyndai
Malacos Properties, LTD
Massachusetts General Hospital Cancer Center
Mansfield Jackie Mansfield
Marble Slab Creamery
Margaret and Donald Austin Family Foundation
Mariner Real Estate
Management, LLC
Mariner Wealth Advisors
Marylou’s Coffee
The Marksmen Company
Maslin Foundation
Massapequa Turkey Trot
Massapequa Youth Lacrosse Club
Michael Maser
Kim and Matthew Mausser
Steve and Sherry Mayer*
Mayo Clinic Scottsdale
Mary Whelan Levine
Mary and Lawrence Liebscher
Connie Lindsey
The Lipman Family
James Lippman
Lisi
Kim and James R. Lites
Little Treasures Inc.
Brian Littleton
LMI
Lockheed Martin
Lockton Companies
Lord & Taylor
Hogan Lovells
Luken’s Fund
<table>
<thead>
<tr>
<th>DONORS (CONTINUED)</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Neumonitoring</td>
</tr>
<tr>
<td>National Rural Utilities Cooperative Finance Corporation</td>
</tr>
<tr>
<td>Nationwide Children’s Hospital</td>
</tr>
<tr>
<td>Nautripे Berry Growers, Inc.</td>
</tr>
<tr>
<td>Navarro Discount Pharmacy</td>
</tr>
<tr>
<td>Nestle Purina Pet Care Company</td>
</tr>
<tr>
<td>NetSuite</td>
</tr>
<tr>
<td>The Leukemia &amp; Lymphoma Society</td>
</tr>
<tr>
<td>research</td>
</tr>
<tr>
<td>public policy</td>
</tr>
<tr>
<td>patient services</td>
</tr>
<tr>
<td>campaign</td>
</tr>
<tr>
<td>Peake BMW</td>
</tr>
<tr>
<td>Lauren Pearson</td>
</tr>
<tr>
<td>Peck Madigan Jones &amp; Stewart, Inc.</td>
</tr>
<tr>
<td>Pennant Foods Corporation DBA Wendy’s</td>
</tr>
<tr>
<td>Mark and Mary Pennington</td>
</tr>
<tr>
<td>Performance Automotive Network Performance Truck Sales, Inc.</td>
</tr>
<tr>
<td>PerkinElmer Foundation</td>
</tr>
<tr>
<td>Perkins + Will</td>
</tr>
<tr>
<td>Jon Perkins</td>
</tr>
<tr>
<td>Perry Homes</td>
</tr>
<tr>
<td>Peter &amp; Joanne Brown Foundation</td>
</tr>
<tr>
<td>Sheldon and Donita Petersen</td>
</tr>
<tr>
<td>PGA TOUR SuperStore</td>
</tr>
<tr>
<td>Amber Tuyen Pham</td>
</tr>
<tr>
<td>Phase Foundation</td>
</tr>
<tr>
<td>Tom Philbrick, MD</td>
</tr>
<tr>
<td>The Phyllis M. Coors Foundation Sarah Pietrafa</td>
</tr>
<tr>
<td>Pilot Flying J</td>
</tr>
<tr>
<td>Pilot’s Closet/Clothes Mentor/ Once Upon A Child</td>
</tr>
<tr>
<td>Polk Brothers Foundation</td>
</tr>
<tr>
<td>Polo Ralph Lauren Foundation Jim and Kathy Polesinli</td>
</tr>
<tr>
<td>The Portmann Family Charitable Fund</td>
</tr>
<tr>
<td>PotashCorp</td>
</tr>
<tr>
<td>Powell Industries Pranger Family Foundation</td>
</tr>
<tr>
<td>Presidential Detailing</td>
</tr>
<tr>
<td>Presido</td>
</tr>
<tr>
<td>Lee and Amy Pessler Sheldon Pessler</td>
</tr>
<tr>
<td>Price Chopper Supermarkets Donald Proctor</td>
</tr>
<tr>
<td>Property Market Group Prothera Biosciences, Inc. Provision Health Alliance</td>
</tr>
<tr>
<td>PSAV Presentation Services PSEG</td>
</tr>
<tr>
<td>Quanta Services Management, LP Cary Queen</td>
</tr>
<tr>
<td>Rahr Matling Co.</td>
</tr>
<tr>
<td>The Randy and Deborah Daniel Family Charitable Foundation</td>
</tr>
<tr>
<td>The Raymond &amp; Rita Foos Family Charitable Foundation</td>
</tr>
<tr>
<td>Richard Ramsden</td>
</tr>
<tr>
<td>Raynier Institute &amp; Foundation</td>
</tr>
<tr>
<td>RBC Capital Markets</td>
</tr>
<tr>
<td>RBW Logistics</td>
</tr>
<tr>
<td>Real Estate One Charitable Foundation</td>
</tr>
<tr>
<td>Reece Holbrook Win Anyway Foundation Inc. Mark Regante</td>
</tr>
<tr>
<td>Reliant, an NRG Company Richard M. Rendina Republic National Distributing Company</td>
</tr>
<tr>
<td>James Resnick Rex Healthcare</td>
</tr>
<tr>
<td>Nina Richardson Rick Richman</td>
</tr>
<tr>
<td>PATIENT SERVICES</td>
</tr>
<tr>
<td>PUBLIC POLICY</td>
</tr>
<tr>
<td>RESEARCH</td>
</tr>
<tr>
<td>CAMPAIGN</td>
</tr>
</tbody>
</table>
Elaine Weisman
Weldon Service & Repair
WellHealth Quality Care
Wellpoint
Wells Fargo Private Bank
The Wendy’s Company
Tim Welde
The West Endowment
West Marine
Penny Westfall
Wiclund Warrior Fund
Mark and Jessie Wiktor
Curtis Wilker
WILL Grain
William G. Pomeroy Foundation
William J. Shaw Family Foundation
Williams & Connolly LLP
Greg and Wallace Williams
Willis Auto Campus
Willis Foundation
Winsted
Winston & Strawn LLP
Lynn and Mark Witmer
WIVB-TV, Channel 4/CW 23
WQMQ
Woman’s Club of Hermosa Beach
World Bank Community Connection Fund
World Travel Holdings
World Wide Technology, Inc.
Marie Yanney
Eric, Tamara, and Nicholas Yollick
Adelaide W. Zabriskie
Lynne Zaccaria
Zaxby’s
Cathy and Scott Zellinger
Zuehl Family Fundraiser
Supported by the Roaming Skull
Joseph Zsvesper
Anonymous (18)

**TOP CAMPAIGN FUNDRAISERS**

*Schools that have raised more than $25,000, individuals who have raised more than $50,000 or company/teams that have raised more than $100,000 to support LLS’s mission.*

Guy Adami
Margaret and Chuck Altken
Dean Albrecht
Alex and Ani
Helen Anbinder
Michael Anderson
Suzanne Anderson
Dr. Babis Andreadis
Russ Armstrong
At Home
Trey Axe
Sam Azar
Lindsey Baier
Bailey’s Cancer Busters
Emily Baird
Baker Botts LLP
Barclay Bishop and Team Barclay’s Believers
Barclays
Carole Barta
D. Mark Barnhart
Marrianna Barringer
BDI
Sarah Bender
Shannon Wolfson Bentle
Bill Rawlings and Team
Someday is Today
Barclay Bishop
The Blackstone Group
BMC
Katy Dix Braehler
Carly Brasseaux
Brian Fuller and Team Full of Life
Molly Brickler
Morris Brown
Cole Bryan
Patrick Byrne
Burlington
Mal Caldwell
Cancer Treatment Centers of America
Robert “Spider” Cantley
David Carr
Michael Carraway
Mary Carrillo
James W. Carter, IV
Carter’s Inc.
Angela Casale
Eva L. Casale
Jessica and Kirk Cassidy
Celgene Corporation
Neerja Chaudhry
Christbridge Academy
John Clamme
Tiffanie Clausewitz
Brandon Clay
Aimee Clinkenbeard
The Cohan Cup
Gary Cohen
Dr. Colón
Dr. Alessandra Colon
Colton’s Army
Colton and Case Matter
Bianna Conticelli
Bridget Cook
Gina Cook
Brett Cooper
Lisa Cooper
Marcus Conwin
Crenshaw Team
Grace Cruickshank
Trey Cunningham
Frand D’Alessandro
Lauren Dallas
Timothy Daly
Capri D’Amario
Shannon Darnell
Ann Davis
Deelotte
Dr. Anthony DeLuise
Erika Dimson
Discount Tire
Disney Team MA Chapter
Mary Dixon
Matthew Dorsey
Abby Douglas and Julia Davis
Devan Driscoll-Roach
Audrey Duffy
Sarah Edwards
Dr. Babak Eghbali
Elbit Systems of America
EY
Michael Faurest
Cameron Fay & Team Ganbattel
Lauren Fernandez
Jen Fertenthal
Finish Line
Vincent Fiordilino
FIS
Liam Fitzgerald
Stephanie Flux
Jason Fleischer
Kelly Floyd
Michael Foster
Shannon Foster
Nelson M. Francis
Tracy Fritts
Brian Fuller
Grant M. Gaines
Chris Gannon
Hillary Gefman
Genentech/Biogen Idec
Dr. Todd Gersten
Anne Giglio
Gilead
Dr. Frank Glass
Duncan and Fire Giew
Global Franchise Group
Goldman Sachs
Lisa Goldsmith
Francisco Gonzalez
Sue Ellen Goss
Karen Grace
Kristin Guerra
Berensie Guerrero
Ozzie Guillen, Jr.
Wes Gullett
Vishal Gurbuxani
Bianna Haag
Philippo Haddad
Summer Hall
Claire Harmer
Tracy Harrison
Lee Haydu
Lisa Henderson
Vera Herbert
Heritage Trails Elementary
Katie Simmons Hickey
Sandy Hickey
John Hite
Elizabeth Hogan
Constance Howlett
Tommy Hughes
Kat Hurd
I Run With Coach Joe
IHOP
Megan Imbert
Dia Iorlano & “Team Lemonade”
Tamara Jack
Sean Jackson & “Never Give Up”
Matt Jeffrey
Adela Jimenez
Johnny & the SuperHeroes
Just Cure It
Julie Karg
Katie’s Crew
Ali Kavianpour
Katie Kelly
Janet Kiburz
Porschia Kidd
Reree King
Kiven, Kotler, Lieberman, Fox,
Goldschmidt & Kepes
Stacy Kornetzke
Josh Kosnick
KPMG
Niccole and Jeremy Kroll
Maverick Kuhn and Abby
Fitzgerald
Dr. Martha Lacy
Dallas and Team The Dallas
Darlings
Brenda D. Lavel
Melissa Leatherbury
Gary Leff
Quen Leonard
Damione Lewis
Jackson Lewis
Bill Lia, Jr.
Nick Linca
Dr. Alexis Lipton
LLS National Office Greene Team
Sarah Lott
Molly Magnuson
Daw Malacos
Peter and Gina Manos
Dr. Matt Marinella
Jeremy Matza
Lisa Maurer
DOANS (CONTINUED)

Dee Dee McCarron
Rumiko McCarthy
JT McDaiden
Chris McFarland
Kelly McGee
Nicole McGlothlin
Jessica Meyer
George Meza
Dr. Adam Mezoff
Michael Carraway and Team Carraway for a Cure
Freddy Mistry
Kathy Moeder
Jessica Moore
Dana Moraci
Inez Moriarty
Blake Morris
Brint Morrow
Kyle Mostransky
Paul Mozocci
Benymulune, PharmD
Casey Munck
Dina Mrushik & Together To Cure
Craig Murray
Megan Murray
National Capital Area MWOY
Leadership Team
Annie Nemeck
Tiffany Nguyen; Erin Macbeth
Jeffrey J. Nielson
Lynne O’Brien
Dominick Oliviero
Osborn Park High School
David Panico
Partners For A Cure
Dr. Anjan Patel
Mary Pennington
Pharmacyclics/Janssen
Alex Pinelo
John Pinkerton
Robby Potate
Greg Poulos
Lee Pressler
Tim Price
PV
PwC
Brittane Hammond Quigley
Erin Ragdaler
Rampant High School
Dr. Brian Randolph
Dr. Brion Randolph and Team Heme
Scott Randolph
Randy & Kathy Reunion Tour
Dr. Arati V. Rao
Liz Rapp
Carol Rausch
Bill Rawlings
Re-Remission for Ryan
Rebecca Sterner and Team The Rockin’ Raisers
Rylan Reed
Mike Reynold
Troy Rice
Sara Richburg
Ride For Ron
Riders of the Storm
Mark Rodgers
Jennifer Rogers and Robert Carlock
Kevin Rohalmin
Christi Rotterdam
Justin Royle
Josh Rubinstein
Salesforce.com
David Salinas
Sarah Cannon Blood Cancer Network
Stephanie Sanders
Sandisk
Tim Sargent
Cody Scarborough
SCDS Wildcat Climbers
Aaron Schirin
Tom Schmidt
Allison Schnall
Julie Schneider
Scott Schweighauser
Helena Scott
SDG&E / Sempra
Seattle Fire – Team Tristan Smith
Seattle Genetics
Dr. Sheila Shahabi
Martha Shaker
Kevin Shannahann
Leana Shefman
Dr. Shahazad Siddique
Jon Silcox
Megan Sierveyrd Simpson
Stephanie Simpson
Ariya Siatisky
Chris Small
Denise Smith
Kieran Smith
Luke K. Smith
Society Ties – NYC
Tony Sorrentino
Dr. David Stapor
Stater Bros. Charities
Thomas H. Steele
Amanda Steffy
Rebecca Sterner
Stewart School
Stratford School, Curtis Campus
Adam Sussman
Suzanne Anderson, MD and Team Grateful Times Ten
Takeda Pharmaceuticals USA, Inc. & Affiliates
Leslie Tatel
Team Answer for Cancer
Team Audrey
Team Bacon Bits
Team Believe
Team Blumenfeld & Waterman
Team CURE
Team Debbia
Team Dennewitz
Team Diana
Team Driscoll’s
Team EJ
Team Foundry/Anthony DeLuise
Team G.A.L.
Team Jordan: Doing it for Emily
Team Kim
Team Laubach
Team LOL
Team Medtronic
Team Murawski
Team Natasha
Team on Fire
Team Paolini
Team Princess Margo/Powered by Kailie’s Krew
Team Reinhart
Team Sally
Team Town Star/Subway
Team Waddell & Reed/Ivy Funds
Teva Oncology
Elizabeth (Libba) Thompson
Meya Thukral
Paul Titterington
Sonia Toledo
Sarah Topy
Team Town Star/Subway
Kelly Treinen
Cindy Tripp
Brad Tucker
Turning 10
Katya Unsta
Megan Van PetL
Monica Vasquez
Alexandra von Plato
Vistar
VITAS Innovative Hospice Care
Wallgreens
Walt Whitman High School
Walter Johnson High School
Brian Ward
Jenna D. Wardle
The Warriors
Washington Gas
Brian Waterman
Watertown Middle School
Dan Waugh
Jason Weiner
Rob Welker
Wells Fargo
Ronald M. Wolf, DDS, MS
Shannon Watson
Finlay Woodruff
Amanda W. Yopp
Cynthia Yosha-Snyder
Benjamin Zangolia

Legacy Circle honors those who designate LLS as a beneficiary of their will, trust, retirement account or insurance policy, or fund a charitable gift annuity. We list our newest members below along with those whose bequests of $10,000 or more were received this year.

Eli Bakshi
Mary Baumgardner
Norman and Betty Bertaux
Mary Ann Bland
Edith Blankenship
Dorothy Booth
Robert Borsch
Erwin Brandt
Susan Branson
Mr. and Mrs. Peter Brock
Joanne Burgett
Angeline Capperrino
Marjolair Carus
Gertraude Coleman
Rodger and Lorie Coon
Mildred Crespin-Croegaert
Margaret DiDonato
Julian Dodge
Peggy and Margaret Dupaquier
Chester Elkind
Cynthia Fay
Rosabelle Fetty
Nelle Fishman
John Frekves
Stella Frekves
Carole Gardener
Ronald Theodore Gibson
Joseph Gilbert
Wesley Gladov
Charles Godchaux
Becky Godchaux
Rebecca Grajevski
Howard Grant
Mildred Grossman
Carolyn Hamilton
Joanne Hastings
Bernice Houllian
Miriam Kaplan
Dr. Judith Karp and Stanley Freedman
Ellen Kemper
Thomas Keys
Evelyn Kiker
Barbara Kirsh
Allen Klein

Fred Kohler and Kuo-Jung Chang
Peter Landecker
Virgil Levi
H. Eleanor Lodholz
Jennifer McGuire
Helen Jean Mellous
Ernest Newman
Michael Pechanach
I. Edward Picker
Siegfried and Pamela Pinchut
Robert and Cheryl Post
Edna Raupp
Jennifer Rodrigues
FlorenceRubino
Robert Ruhe
Anita Schlacht
Juanita Joyce Scholop
Etheh Schwarzman
Gail Secrist
Bruno and Irma Selmi
Gerogia Shank
Elisabeth Situm
Georgiana Slanski-Lee
David R. Smith
Sidney M. Steiger
(In Memory of Vivian Blumberg Steiger)
Judith Ann Stimson
Lois Stockett
William Stockett
Bruce Swartz
Lois Mary Elaine Teisciero
Leila Valentine
Bernard and Christa VanderLinden
William Vaughan
Estella Ruth Watts
Hannah Weiss
Jill Westhead
Lars and Carol Wigert
Richard Woody
Stanley Zaring
John and Mary Zick
Rosalyn Zohn

* National Man & Woman of the Year
* Deceased
INDEPENDENT AUDITORS’ REPORT

The Board of Directors
The Leukemia & Lymphoma Society, Inc.

We have audited the accompanying consolidated financial statements of The Leukemia & Lymphoma Society, Inc. (LLS), which comprise the consolidated balance sheet as of June 30, 2015, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

MANAGEMENT’S RESPONSIBILITY FOR THE FINANCIAL STATEMENTS Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

AUDITORS’ RESPONSIBILITY Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

OPINION In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2015, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

REPORT ON SUMMARIZED COMPARATIVE INFORMATION We have previously audited LLS’s consolidated financial statements, and we expressed an unmodified opinion on those audited consolidated financial statements in our report dated October 15, 2014. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2014 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

KPMG LLP

October 21, 2015
# CONSOLIDATED BALANCE SHEET

The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with comparative amounts at June 30, 2014) (In thousands)

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents (note 3)</td>
<td>$52,897</td>
<td>$28,771</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>6,049</td>
<td>5,362</td>
</tr>
<tr>
<td>Legacies and contributions receivable, net (note 5)</td>
<td>8,989</td>
<td>9,113</td>
</tr>
<tr>
<td>Investments (note 3)</td>
<td>137,941</td>
<td>188,885</td>
</tr>
<tr>
<td>Fixed assets, net (note 7)</td>
<td>14,826</td>
<td>16,604</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$220,702</td>
<td>248,735</td>
</tr>
</tbody>
</table>

| **Liabilities and Net Assets** |          |          |
| Liabilities:                |          |          |
| Accounts payable and accrued expenses | $18,416  | 20,685   |
| Deferred revenue (note 6)    | 17,802   | 26,745   |
| Awards and grants payable (note 2) | 69,335   | 84,201   |
| Co-Pay assistance payable (note 2) | 14,465   | 16,698   |
| **Total liabilities**        | 120,018  | 148,329  |

| Commitments and contingencies (notes 2 and 9) |          |          |
| Net assets (note 4):                  |          |          |
| Unrestricted                          | 72,848   | 68,842   |
| Temporarily restricted                | 24,146   | 27,989   |
| Permanently restricted                | 3,690    | 3,575    |
| **Total net assets**                  | 100,684  | 100,406  |
| **Total liabilities and net assets**  | $220,702 | 248,735  |

*See accompanying notes to consolidated financial statements.*
CONSORTIUM OF STATEMENT OF ACTIVITIES
The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with summarized totals for the year ended June 30, 2014) (In thousands)

<table>
<thead>
<tr>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total 2015</th>
<th>Total 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Operating Revenue</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Campaign contributions</td>
<td>$236,171</td>
<td>23,258</td>
<td>—</td>
<td>259,429</td>
</tr>
<tr>
<td>Less direct donor benefit costs</td>
<td>(24,606)</td>
<td>—</td>
<td>—</td>
<td>(24,606)</td>
</tr>
<tr>
<td>Net campaign contributions</td>
<td>211,565</td>
<td>23,258</td>
<td>—</td>
<td>234,823</td>
</tr>
<tr>
<td>Co-pay contributions</td>
<td>—</td>
<td>43,000</td>
<td>—</td>
<td>43,000</td>
</tr>
<tr>
<td>Legacies</td>
<td>9,998</td>
<td>159</td>
<td>—</td>
<td>10,157</td>
</tr>
<tr>
<td>Donated services and media (note 6)</td>
<td>9,864</td>
<td>—</td>
<td>—</td>
<td>9,864</td>
</tr>
<tr>
<td>Net interest and dividend income</td>
<td>1,802</td>
<td>59</td>
<td>43</td>
<td>1,904</td>
</tr>
<tr>
<td>Net assets released from restrictions (note 2):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-pay assistance</td>
<td>41,804</td>
<td>(41,804)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Satisfaction of other donor restrictions</td>
<td>28,755</td>
<td>(28,755)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total operating revenue</strong></td>
<td>303,788</td>
<td>(4,083)</td>
<td>43</td>
<td>299,748</td>
</tr>
<tr>
<td><strong>Operating Expenses (note 10)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program services:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td>71,540</td>
<td>—</td>
<td>—</td>
<td>71,540</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>95,526</td>
<td>—</td>
<td>—</td>
<td>95,526</td>
</tr>
<tr>
<td>Public health education</td>
<td>36,249</td>
<td>—</td>
<td>—</td>
<td>36,249</td>
</tr>
<tr>
<td>Professional education</td>
<td>16,829</td>
<td>—</td>
<td>—</td>
<td>16,829</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td>220,144</td>
<td>—</td>
<td>—</td>
<td>220,144</td>
</tr>
<tr>
<td>Supporting services:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and general</td>
<td>31,006</td>
<td>—</td>
<td>—</td>
<td>31,006</td>
</tr>
<tr>
<td>Fund raising</td>
<td>46,205</td>
<td>—</td>
<td>—</td>
<td>46,205</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td>77,211</td>
<td>—</td>
<td>—</td>
<td>77,211</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>297,355</td>
<td>—</td>
<td>—</td>
<td>297,355</td>
</tr>
<tr>
<td>Change in net assets from operating activities</td>
<td>6,433</td>
<td>(4,083)</td>
<td>43</td>
<td>2,393</td>
</tr>
<tr>
<td>Write-off of contribution receivable (note 5)</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Foreign currency translation adjustment</td>
<td>(530)</td>
<td>—</td>
<td>—</td>
<td>(530)</td>
</tr>
<tr>
<td>Net (decrease) increase in fair value of investments (note 3)</td>
<td>(1,897)</td>
<td>240</td>
<td>72</td>
<td>(1,585)</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td>4,006</td>
<td>(3,843)</td>
<td>115</td>
<td>278</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beginning of year</td>
<td>$68,842</td>
<td>27,989</td>
<td>3,575</td>
<td>100,406</td>
</tr>
<tr>
<td>End of year</td>
<td>72,848</td>
<td>24,146</td>
<td>3,690</td>
<td>100,684</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
## CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES

The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with comparative totals for the year ended June 30, 2014) (In thousands)

### Program Services

<table>
<thead>
<tr>
<th>Patient and community service</th>
<th>Public health education</th>
<th>Professional education</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Awards and grants (note 2)</strong></td>
<td>53,717</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Therapy acceleration program (note 2)</strong></td>
<td>13,503</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Financial aid to patients</strong></td>
<td>—</td>
<td>430</td>
<td>430</td>
</tr>
<tr>
<td><strong>Co-pay assistance (note 2)</strong></td>
<td>—</td>
<td>41,804</td>
<td>41,804</td>
</tr>
<tr>
<td><strong>Co-pay processing fees</strong></td>
<td>—</td>
<td>4,581</td>
<td>4,581</td>
</tr>
<tr>
<td><strong>Donated services and media (note 6)</strong></td>
<td>556</td>
<td>3,912</td>
<td>5,008</td>
</tr>
<tr>
<td><strong>Salaries</strong></td>
<td>2,457</td>
<td>20,103</td>
<td>9,094</td>
</tr>
<tr>
<td><strong>Employee benefits and taxes (note 8)</strong></td>
<td>160</td>
<td>4,390</td>
<td>3,473</td>
</tr>
<tr>
<td><strong>Temporary services</strong></td>
<td>114</td>
<td>1,754</td>
<td>596</td>
</tr>
<tr>
<td><strong>Occupancy (note 9)</strong></td>
<td>26</td>
<td>2,793</td>
<td>747</td>
</tr>
<tr>
<td><strong>Insurance</strong></td>
<td>3</td>
<td>199</td>
<td>90</td>
</tr>
<tr>
<td><strong>Telephone</strong></td>
<td>7</td>
<td>720</td>
<td>339</td>
</tr>
<tr>
<td><strong>Travel</strong></td>
<td>129</td>
<td>1,419</td>
<td>1,328</td>
</tr>
<tr>
<td><strong>Printing, advertising, and supplies</strong></td>
<td>41</td>
<td>3,454</td>
<td>1,132</td>
</tr>
<tr>
<td><strong>Equipment rentals and maintenance</strong></td>
<td>3</td>
<td>1,136</td>
<td>613</td>
</tr>
<tr>
<td><strong>Postage and shipping</strong></td>
<td>1</td>
<td>1,438</td>
<td>1,260</td>
</tr>
<tr>
<td><strong>Meetings</strong></td>
<td>537</td>
<td>459</td>
<td>415</td>
</tr>
<tr>
<td><strong>Professional fees</strong></td>
<td>282</td>
<td>4,696</td>
<td>3,593</td>
</tr>
<tr>
<td><strong>Miscellaneous</strong></td>
<td>1</td>
<td>893</td>
<td>622</td>
</tr>
<tr>
<td><strong>Depreciation and amortization</strong></td>
<td>3</td>
<td>1,345</td>
<td>735</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>71,540</td>
<td>95,526</td>
<td>36,249</td>
</tr>
</tbody>
</table>

### Supporting Services

<table>
<thead>
<tr>
<th>Management and general</th>
<th>Fund raising</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Awards and grants (note 2)</strong></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Therapy acceleration program (note 2)</strong></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Financial aid to patients</strong></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Co-pay assistance (note 2)</strong></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Co-pay processing fees</strong></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Donated services and media (note 6)</strong></td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Salaries</strong></td>
<td>12,055</td>
<td>13,084</td>
</tr>
<tr>
<td><strong>Employee benefits and taxes (note 8)</strong></td>
<td>3,986</td>
<td>3130</td>
</tr>
<tr>
<td><strong>Temporary services</strong></td>
<td>1,156</td>
<td>1,149</td>
</tr>
<tr>
<td><strong>Occupancy (note 9)</strong></td>
<td>1,822</td>
<td>1,831</td>
</tr>
<tr>
<td><strong>Insurance</strong></td>
<td>244</td>
<td>129</td>
</tr>
<tr>
<td><strong>Telephone</strong></td>
<td>416</td>
<td>537</td>
</tr>
<tr>
<td><strong>Travel</strong></td>
<td>753</td>
<td>963</td>
</tr>
<tr>
<td><strong>Printing, advertising, and supplies</strong></td>
<td>2,202</td>
<td>7,657</td>
</tr>
<tr>
<td><strong>Equipment rentals and maintenance</strong></td>
<td>724</td>
<td>670</td>
</tr>
<tr>
<td><strong>Postage and shipping</strong></td>
<td>285</td>
<td>4,261</td>
</tr>
<tr>
<td><strong>Meetings</strong></td>
<td>277</td>
<td>240</td>
</tr>
<tr>
<td><strong>Professional fees</strong></td>
<td>3,889</td>
<td>6,024</td>
</tr>
<tr>
<td><strong>Miscellaneous</strong></td>
<td>716</td>
<td>477</td>
</tr>
<tr>
<td><strong>Depreciation and amortization</strong></td>
<td>2,481</td>
<td>1,197</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>31,006</td>
<td>46,205</td>
</tr>
</tbody>
</table>

### Direct Donor Benefit Costs

<table>
<thead>
<tr>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>53,717</td>
<td>63,716</td>
</tr>
<tr>
<td>13,503</td>
<td>16,107</td>
</tr>
<tr>
<td>430</td>
<td>2,524</td>
</tr>
<tr>
<td>41,804</td>
<td>49,246</td>
</tr>
<tr>
<td>4,581</td>
<td>4,567</td>
</tr>
<tr>
<td>9,864</td>
<td>10,985</td>
</tr>
<tr>
<td>16,519</td>
<td>21,135</td>
</tr>
<tr>
<td>6,222</td>
<td>6,568</td>
</tr>
<tr>
<td>9,566</td>
<td>10,140</td>
</tr>
<tr>
<td>2,276</td>
<td>3,285</td>
</tr>
<tr>
<td>5,214</td>
<td>5,479</td>
</tr>
<tr>
<td>2,630</td>
<td>4,432</td>
</tr>
<tr>
<td>17,446</td>
<td>22,215</td>
</tr>
<tr>
<td>4,181</td>
<td>5,017</td>
</tr>
<tr>
<td>3,580</td>
<td>3,276</td>
</tr>
<tr>
<td>47,838</td>
<td>64,019</td>
</tr>
<tr>
<td>11,135</td>
<td>11,179</td>
</tr>
<tr>
<td>2,866</td>
<td>3,215</td>
</tr>
<tr>
<td>1,723</td>
<td>2,102</td>
</tr>
<tr>
<td>5,361</td>
<td>6,415</td>
</tr>
<tr>
<td>24,606</td>
<td>28,784</td>
</tr>
</tbody>
</table>

### EXPENSES

- **Research** 24.0%
- **Patient and Community Service** 32.1%
- **Public Health Education** 12.2%
- **Professional Education** 5.7%
- **Total Program Services** 74.0%
- **Management and General** 10.4%
- **Fund raising** 15.6%
- **Total Supporting Services** 26.0%
- **TOTAL EXPENSES** 100.0%

See accompanying notes to consolidated financial statements.
CONSORTIUM STATEMENT OF CASH FLOWS
The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with comparative amounts for the year ended June 30, 2014) (In thousands)

<table>
<thead>
<tr>
<th>Cash flows from operating activities:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in net assets</td>
</tr>
<tr>
<td>$ 278</td>
</tr>
<tr>
<td>(3,359)</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets</td>
</tr>
<tr>
<td>to net cash used in operating activities:</td>
</tr>
<tr>
<td>Net decrease (increase) in fair value of investments</td>
</tr>
<tr>
<td>1,585 (12,402)</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
</tr>
<tr>
<td>5,780 3,989</td>
</tr>
<tr>
<td>Provision for uncollectible accounts</td>
</tr>
<tr>
<td>126 (304)</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
</tr>
<tr>
<td>(687) 193</td>
</tr>
<tr>
<td>Legacies and contributions receivable</td>
</tr>
<tr>
<td>(2) (783)</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
</tr>
<tr>
<td>(2,269) (703)</td>
</tr>
<tr>
<td>Deferred revenue</td>
</tr>
<tr>
<td>(8,943) (8,329)</td>
</tr>
<tr>
<td>Awards and grants payable</td>
</tr>
<tr>
<td>(14,866) 9,376</td>
</tr>
<tr>
<td>Co-Pay assistance payable</td>
</tr>
<tr>
<td>(2,233) 9,461</td>
</tr>
<tr>
<td>Net cash used in operating activities</td>
</tr>
<tr>
<td>(21,231) (2,861)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cash flows from investing activities:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purchases of fixed assets</td>
</tr>
<tr>
<td>(4,002) (9,740)</td>
</tr>
<tr>
<td>Purchases of investments</td>
</tr>
<tr>
<td>(36,640) (77,132)</td>
</tr>
<tr>
<td>Sales of investments</td>
</tr>
<tr>
<td>85,999 91,204</td>
</tr>
<tr>
<td>Net cash provided by investing activities</td>
</tr>
<tr>
<td>45,357 4,332</td>
</tr>
<tr>
<td>Net increase in cash and cash equivalents</td>
</tr>
<tr>
<td>24,126 1,471</td>
</tr>
</tbody>
</table>

Cash and cash equivalents at beginning of year
28,771 27,300

Cash and cash equivalents at end of year
$ 52,897 28,771

See accompanying notes to consolidated financial statements.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The Leukemia & Lymphoma Society, Inc. / June 30, 2015 (with comparative amounts as of and for the year ended June 30, 2014)

1) Organization and Summary of Significant Accounting Policies

A) ORGANIZATION
The Leukemia & Lymphoma Society, Inc. (LLS) is the world’s largest voluntary health agency dedicated to finding cures for blood cancers. LLS’s mission is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma and improve the quality of life of patients and their families. LLS research grants have funded many of today’s most promising advances for the treatment of blood cancer patients, including targeted therapies and immunotherapies. LLS is a leading source of publicly available information for blood cancer, education and support, and influences policies that accelerate the development and approval of new blood cancer therapies. LLS advocates for blood cancer patients and their families, helping patients navigate their cancer treatments and ensuring they have access to quality, affordable and coordinated care. LLS is dedicated to removing barriers to care by representing the healthcare and medical research interests of patients and families to policy makers at all levels of government.

B) TAX-EXEMPT STATUS
LLS qualifies as a charitable organization as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, is exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since LLS is publicly supported, contributions to LLS qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

LLS recognizes the effect of income tax positions only if those tax positions are more likely than not to be sustained. Income generated from activities unrelated to LLS’s exempt purpose is subject to tax under Internal Revenue Code Section 511. LLS did not recognize any unrelated business income tax liability for the years ended June 30, 2015 and 2014.

C) PRINCIPLES OF CONSOLIDATION
The accompanying consolidated financial statements include the accounts of LLS, which encompasses the National Office of LLS and its fifty-four chapters in the United States, and LLS’s not-for-profit affiliates, LLSC and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc., and The Leukemia & Lymphoma Society Research Foundation. All significant intercompany and intra-LLS accounts and transactions have been eliminated in consolidation.

D) ESTIMATES
The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS’s management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include the fair value of alternative investments, allowance for uncollectible accounts, allocation of expenses, and valuation of donated services and media. Actual results could differ from those estimates.

E) RISKS AND UNCERTAINTIES
LLS invests in various investment securities. Investment securities are exposed to various risks such as interest rate risks, fluctuations in market values, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

LLS’s principal source of revenue is amounts contributed by the general public. Accordingly, LLS’s operations are affected by individual contributions, which are affected by general economic conditions, employment levels, and other factors over which LLS has little or no control. By contrast to the granularity of the general public donations, the co-pay program in 2015 and 2014 was funded by eight and six donors, respectively.

F) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The consolidated financial statements are presented with 2014 summarized or comparative information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2014 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS’s 2014 consolidated financial statements from which the summarized information was derived.

G) SUBSEQUENT EVENTS
LLS evaluated subsequent events after the balance sheet date of June 30, 2015 through October 21, 2015, which was the date the consolidated financial statements were issued, and noted one additional required disclosure.

On September 15, 2015, LLS entered into a 15 year lease for 41,868 square feet of space for its National Office beginning no earlier than April 1, 2016. The lease terms provide for one year of rent abatement. Future minimum rental lease commitments under the lease are approximately $1,005,000 annually for the next five years.

H) NET ASSET CLASSIFICATIONS
To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into three net asset categories as follows:

Unrestricted net assets: Consist of funds that are fully available, at the discretion of LLS’s Board of Directors, for LLS to utilize in any of its programs or supporting services.

Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific time period and/or purpose.

Permanently restricted net assets: Consist of funds that contain donor-imposed restrictions requiring that the principal be invested in perpetuity. Income earned on these funds are recorded as temporarily restricted net assets and are released from restriction when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board-approved spending policy (note 4).

I) FOREIGN CURRENCY TRANSLATION
LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

J) FAIR VALUE MEASUREMENTS
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.

Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 unobservable inputs for the asset or liability.
LLS follows the provisions of Accounting Standards Codification (ASC) 820, Fair Value Measurement, for its alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value per share or its equivalent, as reported by the investment managers. The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment's underlying assets and liabilities.

The carrying value of cash and cash equivalents, accounts payable and accrued expenses, and grants payable approximates fair value because of their short term nature.

In 2015, LLS early adopted the provisions of Accounting Standards Update No. 2015-07, Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent), which removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient and removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. LLS applied the provision of the update retrospectively to 2014.

KL) CONTRIBUTIONS, GRANTS AND DEFERRED REVENUE
Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met. Certain grants are accounted for as exchange transactions whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

L) DONATED SERVICES
LLS has determined that certain of the donated services it receives meet the criteria for recognition in the consolidated financial statements. The value of contributed services was determined for volunteers that possess specialized skills, and would otherwise need to be purchased. These services are recognized as revenue and expense.

M) DONATED MEDIA
LLS has conducted national public service announcements (PSA) media campaigns and benefited from donated media time that was aired on television and radio. The value of contributed media, which is recognized in the financial statements, was estimated based on the placement, audience, and demographics of the PSAs.

N) CASH EQUIVALENTS
Cash equivalents consist of short-term investments with an original maturity of three months or less from date of purchase, except for amounts held in investments.

O) INVESTMENTS
Investments are stated at fair value based upon quoted market prices, except for the fair values of alternative investments which are based on net asset values provided by the fund managers or general partners, based upon the underlying net assets of the funds consistent with the concepts of ASC 820. These values are reviewed and evaluated by management.

### FIXED ASSETS AND DEPRECIATION
Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter, ranging 2 to 10 years (leasehold improvements 7 years; furniture, fixtures, and office equipment 7 to 10 years, and computer equipment and software 2 to 5 years).

### PROFESSIONAL FEES
Professional fees included in the consolidated financial statements principally include professional fund-raising fees, contracted software development, and legal and auditing fees.

### RECLASSIFICATIONS
Certain reclassifications of 2014 amounts have been made to conform to the 2015 presentation.

## 2) Research and Co-Pay Assistance Program
LLS has various activities that are utilized to carry out its mission as presented below:

### RESEARCH
Awards and Grants: Awards and grants for research are approved by LLS’s Board of Directors and are recognized as expense when contractual conditions have been satisfied. The budgets for multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has multi-year grant commitments of $51,612,000 at June 30, 2015 which are conditioned upon future events and, accordingly, are not recorded. LLS has unconditional grants payable of $69,335,000 and $84,201,000 at June 30, 2015 and 2014, respectively, which are anticipated to be paid in the next year. Grant refunds of approximately $3,104,000 and $821,000 as of June 30, 2015 and 2014, respectively, have been netted against awards and grants expense.

Therapy Acceleration Program (TAP): TAP is LLS’s strategic initiative to speed the development of blood-cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug-enabling studies and clinical-stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi-year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has contract commitments of $20,842,000 and $28,575,000 at June 30, 2015 and 2014, respectively, that are conditioned upon future events and, accordingly, are not recorded.

Commitments for the awards and grants and TAP programs are contingent upon the satisfactory completion of milestones and/or other conditions in the grant and contract agreements. If such conditions are satisfied, the amounts are estimated to be paid as follows (in thousands):

<table>
<thead>
<tr>
<th>Year ending June 30:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>$ 40,749</td>
</tr>
<tr>
<td>2017</td>
<td>22,279</td>
</tr>
<tr>
<td>2018 and thereafter</td>
<td>9,426</td>
</tr>
<tr>
<td>Total</td>
<td>$ 72,454</td>
</tr>
</tbody>
</table>
Co-Pay Assistance Program: The Co-Pay Assistance program offers financial assistance to patients in meeting their insurance co-pay obligations for prescription medications or private/public health insurance premiums. Amounts awarded under the program are expensed in the year approved based on the available funding in the program. Revenue is recognized when the grants are received while expenses are recognized as patients are approved for participation according to program criteria. Accordingly, LLS has recognized $7,254,000 and $11,707,000 in temporarily restricted revenue as of June 30, 2015 and 2014, respectively, for which the corresponding expense is not recognized until the subsequent fiscal year as patients are approved in the program. At June 30, 2015, temporarily restricted net assets include $7,254,000 received in 2015 which are available for expenditure and are intended to be awarded in fiscal 2016.

The following summarizes the activities of the Co-Pay Assistance program in 2015 and 2014.

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning balance</td>
<td>$11,707</td>
<td>–</td>
</tr>
<tr>
<td>Grant commitments</td>
<td>43,000</td>
<td>67,100</td>
</tr>
<tr>
<td>Amount expended during the year:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct assistance to patients</td>
<td>(41,804)</td>
<td>(49,246)</td>
</tr>
<tr>
<td>Other expenses incurred and reimbursed under the contract</td>
<td>(5,649)</td>
<td>(6,147)</td>
</tr>
<tr>
<td>Amounts available for expenditures in the next year</td>
<td>$7,254</td>
<td>11,707</td>
</tr>
</tbody>
</table>

3. Investments

The following tables present LLS’s fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2015 and 2014 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds and cash</td>
<td>$18,544</td>
<td>18,544</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long duration fixed income (mutual fund)</td>
<td>27,599</td>
<td>27,599</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Short duration fixed income (mutual fund)</td>
<td>30,222</td>
<td>30,222</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Government securities and other</td>
<td>958</td>
<td>958</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Equities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large cap equity</td>
<td>7,577</td>
<td>7,577</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>International equity</td>
<td>5,355</td>
<td>5,355</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Small/mid cap equity</td>
<td>223</td>
<td>233</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Investments report at net asset value:</td>
<td>$90,478</td>
<td>90,478</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Money market funds and cash</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long duration fixed income (mutual fund)</td>
<td>55,513</td>
<td>55,513</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Short duration fixed income (mutual fund)</td>
<td>33,923</td>
<td>33,923</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Government securities</td>
<td>1,057</td>
<td>1,057</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Equities:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large cap equity</td>
<td>5,594</td>
<td>5,594</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>International equity</td>
<td>6,906</td>
<td>6,906</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Small/mid cap equity</td>
<td>1,717</td>
<td>1,717</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Total investments report at net asset value</td>
<td>$130,342</td>
<td>130,342</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

In 2015, LLS liquidated approximately $50,000,000 of its investment portfolio in anticipation of funding grant commitments in fiscal 2016 as discussed in note 2. Such amount is included in cash and cash equivalents at June 30, 2015.

Investment expenses of $866,000 and $1,338,000 have been netted against the net (decrease) increase in fair value of investments for the years ended June 30, 2015 and 2014, respectively. The unrealized (losses) gains were $(4,851,000) and $6,573,000 for the years ended June 30, 2015 and 2014, respectively.

LLS’s alternative investments are diversified across four investment strategies, as follows:

1. **Multi strategy hedge funds** – represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies and include event driven strategies, distressed debt, merger and other arbitrage, and value investing.

2. **Long/short equities** – primarily investments in funds that, in turn, invest in liquid, marketable securities, attempting to realize gains through the identification of mispriced securities.

3. **Real asset strategy** – passively managed real asset portfolios comprise Real Estate Investment Trust Index, commodities, and global natural resource stocks.

4. **Limited partnership equity indices** – the underlying holdings of the limited partnership equity indices are principally domestic and international marketable securities.
These strategies create indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS’s risk with respect to such transactions is limited to its capital balance in each investment.

LLS’s alternative investments contain various redemption restrictions with required written notice ranging from 1 to 90 days. By contrast, all of LLS’s nonalternative investments are highly liquid and can be redeemed daily without restriction. As of June 30, 2015 and 2014, the following table summarizes the composition of such alternative investments at fair value by the various redemption provisions (in thousands):

<table>
<thead>
<tr>
<th>Redemption period</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily</td>
<td>$6,965</td>
<td>11,200</td>
</tr>
<tr>
<td>Monthly</td>
<td></td>
<td>2,869</td>
</tr>
<tr>
<td>Quarterly</td>
<td>38,075</td>
<td>40,769</td>
</tr>
<tr>
<td>Annual</td>
<td>2,423</td>
<td>3,705</td>
</tr>
<tr>
<td>Total</td>
<td>$47,463</td>
<td>58,543</td>
</tr>
</tbody>
</table>

As of June 30, 2015 and 2014, LLS has no unfunded commitments on its alternative investments.

4] Temporarity and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2015 and 2014 (in thousands):

<table>
<thead>
<tr>
<th>Time restrictions</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temporarily restricted</td>
<td>$607</td>
<td>$1,295</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>3,543</td>
<td>3,270</td>
</tr>
<tr>
<td>Research</td>
<td>11,738</td>
<td>10,724</td>
</tr>
<tr>
<td>Patient service</td>
<td>4,432</td>
<td>2,862</td>
</tr>
<tr>
<td>Co-pay assistance</td>
<td>7,254</td>
<td>11,707</td>
</tr>
<tr>
<td>Other</td>
<td>115</td>
<td>1,461</td>
</tr>
<tr>
<td>Total</td>
<td>24,146</td>
<td>27,989</td>
</tr>
</tbody>
</table>

5] Legacies and Contributions Receivable

LLS’s legacies and contributions receivable at June 30, 2015 and 2014 consist of unconditional promises to give and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Contributions receivables are originally recorded based on discounted cash flows using a risk adjusted discount rate which is considered a Level 3 input in the fair value hierarchy. Amounts are scheduled to be received as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>$7,111</td>
<td>5,301</td>
</tr>
<tr>
<td>1 to 5 years</td>
<td>2,413</td>
<td>4,137</td>
</tr>
<tr>
<td>After 5 years</td>
<td>575</td>
<td>650</td>
</tr>
<tr>
<td>Subtotal</td>
<td>10,099</td>
<td>10,088</td>
</tr>
<tr>
<td>Less:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allowance for uncollectible accounts</td>
<td>(614)</td>
<td>(488)</td>
</tr>
<tr>
<td>Discount to present value (1.5% to 5.0%)</td>
<td>(496)</td>
<td>(487)</td>
</tr>
<tr>
<td>Total</td>
<td>$8,989</td>
<td>9,113</td>
</tr>
</tbody>
</table>

In 2014, a foundation notified LLS that it intended to cancel a grant commitment that was made in the previous year due to a change in the foundation’s objectives. Accordingly, LLS wrote off the balance of the contribution receivable in the amount of $3,507,000.
6] Deferred Revenue, Donated Services and Media

During 2013, LLS received a $20,000,000 grant with the contractual agreement to be utilized on research which is jointly identified by the grantor and LLS. At June 30, 2015 and 2014, the unexpended balance of the grant of $4,504,000 and $13,700,000, respectively, are included in deferred revenue. Revenue under this grant is expected to be recognized over the next year, as expenses are incurred. The remaining balance of deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year end.

The value of donated services for family support group facilitators and research grant reviewers, as well as donated media are included in both revenue and expense as shown below (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donated services</td>
<td>$4,468</td>
<td>$4,985</td>
</tr>
<tr>
<td>Donated media</td>
<td>5,396</td>
<td>6,000</td>
</tr>
<tr>
<td>Total</td>
<td>$9,864</td>
<td>$10,985</td>
</tr>
</tbody>
</table>

7] Fixed Assets, Net

Fixed assets at June 30, 2015 and 2014 consist of the following (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leasehold improvements</td>
<td>$1,109</td>
<td>1,135</td>
</tr>
<tr>
<td>Furniture, fixtures, and other office equipment</td>
<td>2,629</td>
<td>2,646</td>
</tr>
<tr>
<td>Computer equipment and software</td>
<td>31,829</td>
<td>27,913</td>
</tr>
<tr>
<td>Total</td>
<td>$35,567</td>
<td>31,694</td>
</tr>
<tr>
<td>Less accumulated depreciation and amortization</td>
<td>(20,741)</td>
<td>(15,090)</td>
</tr>
<tr>
<td>Fixed assets, net</td>
<td>$14,826</td>
<td>16,604</td>
</tr>
</tbody>
</table>

8] Retirement Plans

LLS has a defined contribution 403(b) pension plan covering all employees meeting age and service requirements. Contributions are based on a percentage of each eligible employee's salary and years of service. Expenses under this plan aggregated $1,858,000 and $4,214,000 for the years ended June 30, 2015 and 2014, respectively.

LLS has 457 deferred compensation plans (the 457 Plans) for its executive staff. The 457 Plans are nonqualified deferred compensation plans subject to the provisions of the Internal Revenue Code Section 457. Expenses under the 457 Plans approximated $10,000 and $296,000 for the years ended June 30, 2015 and 2014, respectively. The assets and liabilities of the 457 Plans are included in investments and accounts payable and accrued expenses in the accompanying consolidated balance sheet and amounted to approximately $1,380,000 and $1,589,000 at June 30, 2015 and 2014, respectively.

9] Lease Commitments

The leases for premises, which LLS’s National Office and chapters occupy, expire on various dates through September 30, 2023 and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses, and utilities. The approximate minimum aggregate future annual rental commitments are summarized as follows (in thousands):

<table>
<thead>
<tr>
<th>Year ending June 30:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>$7,483</td>
</tr>
<tr>
<td>2017</td>
<td>5,047</td>
</tr>
<tr>
<td>2018</td>
<td>3,625</td>
</tr>
<tr>
<td>2019</td>
<td>2,567</td>
</tr>
<tr>
<td>2020</td>
<td>2,064</td>
</tr>
<tr>
<td>Therafter</td>
<td>4,321</td>
</tr>
<tr>
<td>Total</td>
<td>$25,107</td>
</tr>
</tbody>
</table>

10] Joint Costs Allocation

For the years ended June 30, 2015 and 2014, LLS incurred expenses to conduct activities that had both fundraising appeals as well as mission program and management and general components (joint activities). Those joint activities included direct mail, coinboards, and media campaigns. Such costs are allocated based on applicable accounting standards and were allocated as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund raising</td>
<td>$15,294</td>
<td>12,645</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>1,152</td>
<td>1,513</td>
</tr>
<tr>
<td>Public health education</td>
<td>3,179</td>
<td>8,486</td>
</tr>
<tr>
<td>Total</td>
<td>$19,625</td>
<td>22,614</td>
</tr>
</tbody>
</table>
NATIONAL LEADERS

Chairman of the Board
James H. Davis, PhD, JD
Palm Beach Gardens, FL

Vice Chair
Elizabeth J. (Betsy) Clark
EJC Consulting
Saugerties, NY

Secretary/Treasurer
Kenneth M. Schwartz
EY
New York, NY

At Large
Donald R. Proctor
Cisco Systems
San Jose, CA

EXECUTIVE LEADERSHIP

Joseph B. Kelley
Lilly USA, LLC
Washington, DC

Ralph E. Lawson
Baptist Health South Florida
Coral Gables, FL

Michelle LeBeau, PhD
University of Chicago
Chicago, IL

THE LEUKEMIA & LYMPHOMA SOCIETY

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA

Board of Directors
James A. Beck
Hefren-Tillotson, Inc.
Butler, PA

William G. Behnke
The Behnke Group
San Antonio, TX

Jorge L. Benitez
CEO Accenture NA, retired
Miami Beach, FL

Jorge E. Bradner, MD
Dana-Farber Cancer Institute
Boston, MA

Peter Bennett Brock
Brock Development Corp.
Palm Beach Gardens, FL

A. Dana Callow, Jr.
Boston Millennia Partners
Boston, MA

Scott A. Carroll, JD
Jackson Lewis
Cincinnati, OH

William S. Dalton, MD, PhD
M2Gen
Tampa, FL

Timothy S. Durst, JD
Baker Botts, LLP
Dallas, TX

Graciela C. Eleta
Eleta Consulting, Inc.
Guaynabo, PR

Bernard H. Garil
Delray Beach, FL

Beth E. Hawley
Cogent HMG
Wayne, PA

Francie Heller
Heller Advisory
New York, NY

Raanan Horowitz
Elbit Systems of America, LLC
Fort Worth, TX

Richard M. Jeanneret
EY
New York, NY

THE LEUKEMIA & LYMPHOMA SOCIETY

Louis J. DeGennaro, PhD
President & CEO

Danielle Gee
Chief of Staff

Andrew S. Coccari, Jr.
Executive Vice President
Chief Product Officer

Rosemarie Loffredo
Executive Vice President
Chief Financial & Administrative Officer

Mark Roithmayr
Executive Vice President
Chief Development Officer

Shelagh Tippet-Fagyas
President
Canadian Operations

THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA

Shelagh Tippet-Fagyas
President
Canadian Operations
mission

cure leukemia, lymphoma, hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.

Share LLS proof. Use this sticker to show your support.

ON THE COVER:
Micayla Wynn, a chronic myeloid leukemia (CML) survivor, takes a targeted oral drug therapy every day to keep her disease in check. Micayla has reached out to LLS for help paying for her regular blood tests.